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Epstein-Barr virus (EBV) is a human herpesvirus, which infects over 90% of the 
world's adult population. It is associated with several malignancies such as 
nasopharyngeal carcinoma (NPC), endemic Burkitt's lymphoma, Hodgkin's Disease and 
some peripheral T cell lymphomas. 
EBV exists in both latent and lytic states. Different patterns of viral gene 
expression have been identified in latently infected cells. Only EBV-encoded nuclear 
antigen (EBNA)l� i s expressed in type I latency. In tumors with a type II latency the 
latent membrane proteins (LMP)l, 2A and 2B and EBNAl are found. In type III latency, 
EBNAl, 2, 3A, 3B, 3C and -LP and LMPl, 2A and 2B are expressed. The immune 
system is able to control EBV infection in normal humans via cytotoxic T-cells (CTLs). 
The strongest response is directed against the EBNA3 proteins with subdominant 
response to all other proteins except EBNAl. BL and NPC shows a type I and II latency 
pattern respectively and there is no expression of the strongly targeted EBNA3 proteins. 
It is expected that switching the pattern to a type IE form of latency with expression of 
immunogenic antigens would enable the tumour to be targeted by preexisting cytotoxic 
T-cells. 
In the case of EBV, methylation of critical transcriptional regulatory elements in 
the C promoter (Cp) prevents expresson of the EBNA proteins other than EBNAl. This 
xiv 
study investigated the alteration of gene expression in the Burkitt's lymphoma cell line, 
Rael, and NPC explants upon treatment with the demethylating agents, 5-azacytidine 
and 5-aza-2-deoxycytidine. 
Two drugs, 5-azacytidine and 5-aza-2-deoxycytidine, are known demethylating 
agents and their effect on promoter usage and associated gene expression in NPC 
explants and cell lines was investigated after in vitro treatment of varied concentrations 
(0-8|LIM) and time periods (24-96 hours). The reverse transcription-polymerase chain 
reaction (RT-PCR) was used to determine the presence of specific RNA transcripts, 
which was confirmed by southern blotting. In addition to changes in gene expression, 
the effect of drug treatment on cell growth and viability was also determined. 
Upon 5-azacytidine and 5-aza-2-deoxycytidine treatment, both cell growth and 
viability were reduced. The EBV expression was limited to BART, LMP2A and EBNAl 
transcripts initiated from the F and Q promotors (Fp and Qp) only in untreated Rael 
cells. After drug treatment, the CpAVp-initiated YUK transcript for EBNAl�EBNA2, 
LMPl and LMP2B transcripts were found. This demonstrated that drug treatment 
caused the expression of EBNA2 and LMP2B, which are potential targets for 
immunotherapy. 
However, in the case of NPC biopsies, no new EBV latent antigens were 
detected after both 5-azacytidine and 5-aza-2-deoxycytidine treatment. Tissue culture 
XV 
protocol was suggested strengthening by enhancing NPC biopsies attachment and 
enriching the tissue culture medium so as to improve the survival and proliferation of the 
biopsies. 
To conclude, this study suggests the effectiveness of altering EBV gene expression 
after treatment with demethylating agents in the Rael cell line. However, effort is still 








在第二類潛伏模式的腫瘤中，可找到潛伏期膜蛋白 (LMP)l , 2A, 2 B 及 









則接受7 2小時0 . 5及的去甲基化劑處理，然後經反轉錄聚合鏈反應法 
(RT-PCR)及Southern印跡以檢測特定的核醣核酸(RNA)轉錄產物的存在。除 
此之外，硏究亦包括此兩種去甲基化劑對細胞生長及存活力的影響。 









Chapter 1 — Introduction 
Chapter 1 Introduction 
1.1 Epstein-Barr Virus 
The Epstein-Barr virus (EBV) is a gamma herpesvirus, which infects over 90% 
of the world's population (Liebowitz & Kieff, 1993). Humans are their exclusive 
natural host. Nearly all children in developing countries are EBV-infected without 
symptoms. Infections occurring in adolescents and young adults results in infectious 
mononucleosis (Kieff, 1996). EBV can directly cause a polyclonal B 
lymphoproliferative disease in immune deficient humans and is an etiologic agent in 
monoclonal B lymphoproliferative disease, Burkitt's lymphoma (BL), Hodgkin's 
disease (HD), unusual T-cell lymphomas, and nasopharyngeal carcinoma (NPC). 
1.1.1 Virus structure 
Like other herpesviruses, EBV has a toroid-shaped protein core that is wrapped 
with DNA, a nucleocapsid with 162 capsomeres, a protein tegument between the 
nucleocapsid and the envelope, and an outer envelope with external glycoprotein 
spikes. The major EBV capsid proteins are 160, 47, and 28 kDa. The most abundant 
EBV envelope and tegument proteins are 350/220 and 152 kDa, respectively (Kieff, 
1996) 
1.1.2 Genome structure 
The EBV genome is composed of a linear, double-stranded, 172-kb DNA 
molecule with characteristic features of a single overall format and gene 
arrangement; reiterated 0.5-kb terminal direct repeats (TR) and reiterated 3-kbp 
1-1 
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internal direct repeats (IR) that divide the genome into short and long largely unique 
sequence domains (US and UL). The unique sequences are composed of several 
perfect or imperfect tandem repeat elements, many of which encode for repeat 
domains in proteins. The genome persists in latently infected cells as an episome 
with a characteristic number of terminal repeats. As each progeny cell tends to have 
EBV episomes with the same number of terminal repeats, latently infected cells 
descending from a common progenitor can be determined (Kieff，1996). 
1.1.3 Nomenclature for EBV open reading frames 
The nomenclature for EBV open reading frames (ORFs) is based on the 
BamHI-restriction fragments. For example� the BARPl ORP is the first rightward 
ORF in the BamHI A fragment, while BZLF2 ORF is the second leftward ORP in 
the BamHI Z fragment (Kieff, 1996). 
1.1.4 Biology of EBV 
EBV is a B-lymphotropic herpesvirus, which infects and immortalizes B cells. 
When performed in vitro, this gives rise to permanently growing lymphoblastoid cell 
lines (LCLs) (Rickinson & Kieff�1996). Such B-cell infection is latent without 
production of infectious virions, and the viral genome is in a circular 
extrachromosomal episome form. In LCL cells, a restricted set of latent viral gene 
products is expressed including 2 small nuclear RNA molecules (EBV-encoded 
RNAs, EBERl and 2)，6 nuclear antigens (EBV-encoded nuclear antigens EBNAl, 
2，3A，3B，3C and LP) and 3 latent membrane proteins (LMPl, 2A and 2B). 
1-2 
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(i) EBER 
The most common viral RNAs in latently infected cells are the EBV-encoded, 
small, non-polyadenylated RNAs (EBER-1 and -2). Their estimated abundance is 
about ICT copies per cell (Howe & Shu, 1989). They are usually transcribed by RNA 
polymerase III and possibly by polymerase II (Howe & Shu, 1989). There are two 
proposed functions of the EBER. Firstly, it is suggested that the EBERs inhibit the 
activation of an interferon-induced protein kinase which blocks transcription by 
phosphorylating the protein-synthesis initiator factor eIF-2 a (Kieff, 1996). 
Secondly, the EBERs are proposed to play a role in the splicing of the primary 
EBNA and LMP mRNA transcripts (Glickman et al., 1988). However, this proposed 
function is incompatible with the observation that EBER is expressed after the 
EBNA and LMP gene expression and initiation of DNA synthesis (Alfieri et al., 
1991). 
(ii) EBNA 1 
EBNAl is a DNA-binding phosphoprotein of about 76kDa. It binds with high 
affinity to the plasmid origin of viral replication, oriP, to initiate replication and 
allows the EBV genome to be maintained as an episome (Kieff, 1996). EBNAl can 
down-regulate its own expression by interacting with two sites immediately down-
stream of the viral Q promoter (Qp) (Nonkwelo et al., 1996). It is also shown to be a 
transcriptional transactivator that can upregulate the C promoter (Cp) and the LMPl 
promoter (Kieff, 1996). EBNAl has been demonstrated to be oncogenic as it leads to 
B cell lymphoma in transgenic mice (Wilson, 1996). 
1-3 
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(in) EBNA2 
EBNA2 is an acidic phosphoprotein located in large nuclear granules. It is 
crucial for B cell transformation (Kieff�1996). It can transcriptionally activate both 
cellular and viral genes, such as modulating the expression of the B cell antigens 
CD21 and CD23 as well as the EBV proteins LMPl and LMP2 (Kieff, 1996, Wang 
et al., 1987, Wang et al., 1990). Moreover, EBNA2 can suppress the expression of 
immunoglubulin M (IgM) (Jochner et al., 1996). It has been shown that EBNA2 
activates the expression of oncogene c-myc (Kaiser et al., 1999). This is suggested to 
be an essential step for EBV-induced proliferation and immortalization. EBNA2 is 
also a transactivator of the EBV latency-associated promoter, Cp, inducing a 
promoter shift from Wp to Cp. It does this by binding with the recombination signal-
binding protein (RBP-JK), which in turn binds to the 5'-GTGGGAA-3' DNA 
sequence in the Cp (Waltzer et al., 1995). 
(iv) EBNA3A, EBNA3B, and EBNA3C 
EBNA3A, EBNA3B and EBNA3C are hydrophilic nuclear proteins. EBV 
recombinant studies have shown that EBNA3A and EBNA3C are essential for B cell 
transformation in vitro (Kieff, 1996). EBNA3B can induce the expression of 
vimentin and CD40 (Silins & Sculley, 1994). 
EBNA3 proteins can associate with the RBP-JK transcription factor, preventing 
it from binding to the cognate JK sequence and to EBNA2 which, in turn, suppresses 
the EBNA2-mediated transactivation of Cp (Radkov et al., 1997; Robertson, 1997). 
Evidence also shows that EBNA3C interacts with human histone deacetylase 1 
1-4 
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(HDACl), which has been suggested to bind to the same or adjacent regions as RBP-
JK (Radkov et al., 1999). This effect contributes to the repression of transcription 
from Cp. Therefore, the EBNA2 and EBNA3 proteins cooperate to modulate the 
RBP-JK activity so as to regulate the expression of cellular and viral promoters 
containing JK cognate sequences (Radkov et al., 1999, Young et al., 2000). 
(V) EBNA-LP 
EBNA-LP is the first EBV-encoded protein expressed and has a variable size 
depending on the number of BamHI W repeats involved (Kieff, 1996). EBNA-LP is 
essential for the efficient outgrowth of LCLs (Allan et al., 1992). It has been shown 
to cooperate with EBNA2 in up-regulating the expression of LMP 1 (Nitsche et al., 
1997). 
(vi) LMPl 
The LMPl protein is located in the cell membrane. LMPl causes up-regulation 
of CD40, CD54 and Bcl-2 family members and inhibition of epithelial differentiation 
and these findings were consistent with its presence in several EBV associated 
tumours, such as immunoblastic lymphoma, Hodgkin's disease, and nasopharyngeal 
carcinoma (Dawson et al.; 1990, Kieff, 1996; Young et al., 1998). LMPl is a viral 
analog of a constitutively active form of CD40, which is a member of the tumour 
necrosis factor (TNF) receptor family. The cytosolic domain of LMPl interacts with 
TNF-receptor-associated factor (TRAF)l, 2, 3 and 5 and the TNF-receptor-
associated death domain (TRADD) (Devergne et al., 1996; Izumi & Kieff，1997; 
Mosialos et aL, 1995). LMPl mimicks the receptor crosslinking effect induced by 
1-5 
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the interaction oftrimeric CD40 ligand with its receptor, resulting in activation of the 
transcription factor NF-KB, which, in turn, causes induction of antiapoptotic A20 
protein expression and interleukin 6 (IL-6) secretion (Floettmann & Rowe, 1997; 
Gires et al., 1997; Eliopoulos et al., 1996; Eliopoulos et al., 1997; Floettmann & 
Rowe, 1997). Moreover, CD40 ligation leads to the activation of c-Jiin N-terminal 
kinase (JNK) which results in the activation of the AP-1 transcription factor family 
(Eliopoulos & Young, 1998; Sutherland et al., 1996). LMPl also activates the p38 
stress activated kinase, which induces up-regulation of IL-8 synthesis and secretion 
(Eliopoulos et al., 1999). Thus, the expression of LMPl leads to both the NF-KB 
mediated transcription of anti-apoptotic genes as well as JNK-pSS pathway-mediated 
apoptosis and oncogenic transformation (Baichwal & Baeuerle�1997; Ip & Davis, 
1998). 
(vii) LMP2 
LMP2 is a hydrophobic membrane protein (Kieff, 1996). The involvement of 
two different promoters results in two different forms of LMP2, namely LMP2A and 
LMP2B, which differ only in the first exon. The first exon of LMP2A encodes a 119 
amino acid N-terminal cytoplasmic domain, whereas that of LMP2B is non-coding 
(Young et al., 2000). Both LMP2A and LMP2B are dispensable for B cell 
transformation (Longnecker, 2000). Two tyrosine residues of the LMP2A N-terminal 
domain construct an immunoreceptor tyrosine-based activation motif (TAM)�which 
is associated with the blockage of B cell receptor (BCR)-stimulated calcium 
mobilisation, tyrosine phosphorylation and the activation of the EBV lytic cycle in B 
cells (Fruehling & Longnecker, 1997; Longnecker, 2000). LMP2B is suggested to be 
1-6 
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a modulator of LMP2A (Longnecker, 2000). 
1.1.5 EBV latency 
Cells latently infected with EBV have different patterns of viral gene expression 
(Table 1.1). Latency I is characterized by expression of the EBERs, EBNAl and 
product of BARFO ORF. It was first recognized in Burkitt's lymphoma. Latency 11 
was first identified in nasopharyngeal carcinoma and is characterized by the 
expression of EBERs, EBNAl, 3 LMPs and the product of BARFO ORF. Latency III 
is found in lymphoblastoid cell lines (LCLs) and immunoblastic lymphomas of 
immunosuppressed patients and is characterized by the expression of all latent viral 
genes. 
Table 1.1 : Latency Patterns of EBV Latent Gene Expression 
Latency Gene product Examples Reference  
I EBERs, EBNAl, BARFO Burkitt's lymphoma Rowe et al .，1987a 
Gastric carcinoma Imai et al1994a 
II EBERS, EBNAl, LMPl, 2A, 2B， Hodgkin's disease Deacon et a!., 1993 
R ARFO 
Nasopharyngeal carcinoma Brooks et al1992 
III EBERs, EBNAl, 2’ 3A，3B, 3C, LP Post-transplant lympho- Young et al1989 ‘ 
LMPl, 2A, 2B, BARFO proliferative disorder 
Infectious mononucleosis Tiemey et al1994 
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1.1.6 EBV latent gene promoters 
Different EBNAs are encoded by individual mRNAs generated by differential 
splicing of the same long "rightward" primary transcript expressed from one of two 
promoters, C promoter and W promoter (Cp and Wp). These two promoters are 
located close together in the BamHI C and W region of the genome (Speck & 
Strominger, 1989). In the case of EBNAl, besides Cp/Wp, it can also be transcribed 
from a promoter in the BamHI Q fragment of the viral genome (Qp) (Brink et al., 
2001). Qp is a TATA-less promoter that resembles house-keeping gene promoters. So 
Qp-initiated EBNA can be found in all EBV-positive cells. Moreover�another 
promoter localized 100-200bp upstream of Qp can also activate EBNAl 
transcription. This is F promoter (Fp), which was found active in cell lines after the 
induction of viral lytic cycle (Nonkwelo et al., 1996). 
The LMP transcripts are expressed from separate promoters in the BamHI N 
region of the EBV genome. There is a bi-directional promoter sequence with the 
leftward LMPl and rightward LMP2B (Kieff, 1996). LMP2A promoter is 
downstream of LMPl promoter (Kieff, 1996). 
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1.2 EBV Infection and Its Persistence 
EBV shedding occurs from the oropharynx and the virus is transmitted through 
saliva from persistently infected to naive individuals. However, the primary site for 
EBV infection has long been controversial. Recent studies suggested that B cells, 
instead of oropharyngeal epithelial cells, are the primary site of EBV infection. In 
patients with infectious mononucleosis, which is a self-limiting lymphoproliferative 
disease associated with primary EBV infection, EBV genomes and gene products are 
readily identified in extrafollicular B-lymphoid blasts but there is no evidence of 
epithelial cell infection by EBV in their tonsils (Niedobitek et al., 1992). In patients 
with X-linked agammaglobulinaemia (XLA), which is an inherited disease 
preventing the development of pre-B cells into mature and functioning B cells, no 
EBV infection has ever been found (Faulkner et al., 1999). 
EBV first comes into contact with B cells in the oropharynx. Inside the 
oropharynx are large lymphoid nodules including the pharyngeal, palatine and 
lingual tonsils. The tonsils are covered externally by squamous epithelium, which 
dips into the connective tissue beneath to form structures known as crypts. The 
reticular epithelium within the crypts is loose so that lymphoid cells can infiltrate 
throughout the epithelial layer, forming 'lymphoepithelium'. 
The mechanism of primary infection with EBV suggested by Faulkner et al is 
similar to that of human immunodeficiency virus (HIV) (Faulkner et al., 2000). 
There are three possible pathways for EBV to penetrate epithelial barriers and enter 
into the B cell compartment of the oropharyngeal mucosa. First, EBV could be 
1-9 
« 
Chapter 1 . Introduction 
capable of crossing intact epithelial layers by transcytosis, which is a vesicular 
transport through epithelial cells in an infection-independent vesicular transport 
manner, and subsequently infect B cells in the underlying lymphoid tissue of the 
tonsil Secondly, EBV could infect B cells stationed in the lymphoepithelium. 
Thirdly, crypt M cells could deliver EBV to the lymphoid tissue beneath the tonsil 
surface. M cells are highly specialized epithelial cells within the lymphoid follicle-
associated epithelium of the gastro-intestinal and respiratory tracts responsible for 
the non-degradative vesicular transport of foreign particles and antigens in order to 
elicit an immune response. 
When a B cell is infected, it is driven into a proliferating B blast (Thorley-
Lawson & Mann, 1985) establishing the lymphoblastoid form of latency (latency III) 
with the expression of latent genes including 6 nuclear proteins and 3 membrane 
proteins, namely, EBNAl, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, 
LMPl, LMP2A and LMP2B (Kieff, 1996). 
The EBV-infected lymphoblasts are similar to normal B blasts activated by 
antigen and T helper (Th) cell at both morphological and phenotypical level. 
However, they employ different mechanisms of activation. In normal B blasts, 
antigen requires Th cell in the form of CD40 ligand and lymphokines to stimulate B 
blast proliferation whereas no Th cell is involved in their EBV-infected counterparts. 
The EBV infects B cells through the binding of its major viral glycoprotein, 
gp350/220, to CD21, the viral receptor (Nemerow et al., 1985). The high density of 
gp350/220 on the virion (Thorley-Lawson & Poodry�1982) causes extensive cross-
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linking of the CD21 signalling complex. Also, a complex of its minor viral 
glycoproteins gH � gL and gp42 binds via gp42 to the MHC class II molecule, which 
is a co-receptor. Such binding provides the necessary signal to initiate the transition 
of B cell from GO to G1 (Sinclair et al； 1994). The expression of latent proteins, 
EBNA2 and EBNA-LP, which originate from the W promoter (Wp) also plays a role 
in driving the cells through the first G1 (Sinclair et al, 1994). EBNA2, being a 
transcription factor, activates other promoters necessary for the full range of latent 
protein expression. At this moment, a promoter switch from Wp to Cp occurs in 
EBNA transcription (Woisetschlaeger et al., 1990). The latent proteins produce a 
series of signals that mimic those from antigen specific Th cells and block terminal 
differentiation so that the B cell becomes activated and enters into the cell cycle in 
which it keeps on proliferating with no differentiation (Thorley-Lawson 8c Babcock, 
1999). 
Several lines of evidence support that the idea that the EBV-infected cell, which 
mimics the known behavior of B cells during a response to an antigen, enters the 
memory compartment via differentiation instead of direct infection. Firstly, LMP 
molecules can imitate the signals for rescuing normal B cells and driving their 
differentiation. Also, the latent viral infection is restricted to resting memory cells 
only. 
Normal B cells are activated by signals from the B cell receptor (BCR) and 
differentiate when they received signals generated by antigen-specific Th cells via 
CD40 and other co-stimulatory molecules. In the case of EBV-infected B cells, these 
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two signals are replaced by those from viral latent proteins, LMPl and LMP2A, 
respectively. 
LMP2A contains a fully functional immunoreceptor tyrosine-based activation 
motif (ITAM) in its amino terminal domain (Longnecker, 2000). This is the same 
motif present on the a and (3 chains of the BCR necessary for signaling upon cognate 
antigen binding. The BCR generates two types of signals. One is responsible for 
initiating the humoral immune response (Liu & Arpin, 1997) while the other is 
required for resting B cell survival (Lam et al” 1997). LMP2A is speculated to 
deliver the BCR rescue signal (Thorley-Lawson & Babcock�1999) as it has been 
shown capable of replacing the BCR in B cell development in Ragl knockout mice 
(Caldwell et aL, 1998). It, thus, provides a surrogate BCR rescue signal to an 
infected B cell. 
LMPl contains a carboxy terminal domain, which has a consensus TNF 
receptor associated factor (TRAF) binding motif and is associated with several 
members of the TRAF family (Kilger et aL, 1998). It performs the signaling function 
of and is functionally interchangeable with the cytoplasmic domain of CD40 (Kilger 
et aL, 1998). In normal B cells, the binding of CD40 to its ligand leads to the 
interaction with TNF receptor associated factors (TRAFs), which are members of a 
family of cytoplasmic molecules. This association activates the cytoplasmic 
transcription factor NPKB, which then translocates to the nucleus and promotes B 
cell survival and growth (Thorley-Lawson & Babcock，1999). However, in EBV-
infected B cells, the NFKB activating function does not map to the T R A F binding 
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motif (Sandberg et aL, 1997). Another mode of signaling may be involved and it 
appears that LMPl promotes B cell growth via a mechanism involving association 
with TRAF molecules and the activation of N F K B (Thorley-Lawson & Babcock, 
1999). LMPl, being a functional homologue of CD40，provides a surrogate Th signal 
to an infected B cell. 
LMPl and LMP2A have the potential to provide the growth and survival signals 
to EBV-infected B blasts. Nevertheless, the key step to initiate the differentiation 
process is to turn off the expression of the transcription factor EBNA2. 
Besides being the transactivator of latent gene promoters, EBNA2 interacts with 
a cellular DNA binding protein called RBPJK (Ling et al., 1994) and is supposed to 
be a functional homologue with NotchlC. Deduced from the suppressive function of 
Notch IC in muscle differentiation, it is speculated that the interaction of EBNA2 
with RBPJK may lead to repressed differentiation with continued proliferation as 
observed in latently infected B blasts (Thorley-Lawson & Babcock, 1999). It was 
demonstrated by Pollack et al that an activated c-myc gene switched off EBNA2 
expression leading to lost expression of latent proteins and cell differentiation 
(Polack et al., 1996). So EBV-infected B blasts become free to differentiate to a 
germinal centre phenotype. At the same time, blockage of the promoters' 
transactivator EBNA2 expression results in the removal of all latent proteins except 
EBNAl, which is essential for the replication and maintenance of the viral genome. 
It is speculated that this kind of EBNAl expression is initiated by Qp, which is not 
activated by EBNA2 (Thorley-Lawson & Babcock，1999). Qp is the unique promoter 
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used in Burkitt's lymphoma cells, which are EBV-positive with EBNAl expression 
only, and is suggested to be a default promoter in non-lymphoblastoid B cells and all 
other non-lymphoid cells (Thorley-Lawson & Babcock�1999). It seemed that 
EBNAl expression will be automatically activated by Qp in case an infected B blast 
transits to a centroblast by down-regulating the latent genes and expressing c-myc 
(Thorley-Lawson & Babcock, 1999). Therefore, blocking the expression of EBNA2 
is believed to play a role in promoting the differentiation of EBV-infected blasts to 
resting memory B cells without eliminating EBNAl expression. 
Once the virus establishes latency in the memory compartment, it persists in the 
host for a lifetime. The frequency of EBV-infected cells in the peripheral blood are 
individual-specific and stable over years (Khan et al., 1996) and these virus-infected 
memory cells evenly express different switched immunoglobulin isotypes (Babcock 
et al., 1998). 
Recent findings showed that a proportion of tonsillar B cells, which are latently 
infected with a phenotype of activated lymphoblasts and latent gene expression 
characteristic of the lymphoblasoid form of latency HI, are frequently present in 
healthy carriers (Joseph et al., 2000). Moreover, these cells are all naiVe B cells, not 
memory B cells. This evidence suggests that specific reinfection is an ongoing 
process in healthy carriers and this is location-restricted. This reinfection would 
result in newly differentiated memory B cells, which would maintain a constant level 
of infected memory cells. This implies that there may be a role for reinfection in the 
long term maintenance of the persistent infection. 
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It is believed that EBV maintains an active equilibrium between production and 
death. They infect naive B cells triggering their proliferation and then differentiate 
into memory B cells. The persistent infection is maintained by periodic activation of 
the latently infected memory cells when they pass through mucosal lymphoid tissue 
generating infectious virus. Reinfection of naive B cells then occurs. 
The importance of host's immune response, primarily CD8+ CTLs, in limiting 
primary infection and in keeping the carrier state in check has been shown by the 
high frequency of EBV-specific CTLs found in the blood of both those with primary 
infection and those in the carrier state. The importance of CTL control of EBV 
infection can be dramatically seen in EBV-driven immunoblastic lymphoblastic 
lymphomas, which can occur in patients that are immunosuppressed either by drug or 
disease. Reversal of the immunosuppression or infusion of EBV-specific CTLs has, 
in many cases, been used to successfully treat the lymphoma. The primary targets of 
these CTLs are the EBNA3 proteins with subdominant responses to EBNA2, EBNA-
LP, LMPl and LMP2 (Lee et al., 2000, Rickinson & Moss, 1997，Rooney et aL, 
1998，Shapiro et al., 1988, Starzl et al., 1984). EBNAl，although expressed in all 
forms of latency is not a target for CTLs as a glycine-alanine repeat domain in the 
protein prevents its processing by the proteasome complex which is necessary for 
recognition by the immune system (Levitskaya et al, 1997). It was proposed that 
EBNAl might have evolved a unique mechanism to avoid class I-restricted CTL 
recognition (Khanna et al., 1992; Murray et al., 1992). Thus, all EBV-infected B 
blasts that express a type HI latency with its immunogenic proteins are eliminated but 
the EBV-infected memory B-cells with a type I latency pattern are not recognized by 
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the immune system and can survive (Babcock et al., 1998). 
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1.3 DNA Methylation 
DNA methylation in eukaryotes involves the addition of a methyl group to the 
carbon 5 position of the cytosine ring by DNA methyltransferase. There are dramatic 
changes in the overall DNA methylation pattern during different periods of 
embryogenesis, development and differentiation to adult cells (Razin & Shemer, 
1995). However, in differentiated cells, methylation patterns are stable with relatively 
little changes and are perpetuated after DNA replication via the high affinity of DNA 
methyltransferase for hemi-methylated DNA (Bestor & Verdine, 1994). 5-
methylcytosine is relatively less stable than cytosine because of its spontaneous 
deamination to uracil. Such mutation results in relative depletion of 5-methylcytosine 
in human DNA leading to germ-line mutation in inherited disease and somatic 
mutations in neoplasia (Zingg & Jones, 1997). The functions of DNA methylation in 
mammalian cells remain unclear despite its involvement in irreversible gene 
inactivation in imprinted genes (Barlow, 1995) and genes on the inactivated X 
chromosomes (Goto & Monk, 1998). 
In mammalian DNA, methylation is normally limited to cytosine followed by a 
guanosine (the CpG dinucleotide). In the human genome, the CpG frequency is 
lower than expected but in some small regions of DNA called "CpG islands", the 
frequency of CpG is normal or higher than expected (Bird, 1986). About half of all 
human genes, including most housekeeping genes, have CpG islands in their 5'-
promoter regions and these are usually immethylated in normal tissues, regardless of 
the transcriptional status of the gene. 
1-17 
f 
Chapter 1 — Introduction 
1.3.1 Aberrant CpG island methylation in cancer 
Neoplastic cells simultaneously have widespread genomic hypomethylation, 
hypermethylation of CpG islands, and increase in DNA-methyltransferase (DNA-
MTase) activity (Baylin et al” 1998). 
Hypomethylation was initially hypothesized to activate oncogenes (Feinberg & 
Vogelstein, 1983) but this has not yet been proved. Hypomethylation is also linked to 
chromosomal instability in vitro (Chen et al., 1998), and is suggested to be involved 
in neoplasia. Both hypomethylation and methyltransferase activation can be found in 
proliferation-induced cells and it is uncertain if the observed changes in malignant 
cells are reflection of cell cycle deregulation (Santini et al,, 2001). 
Hypermethylation has been shown to be associated with transcriptional 
silencing of gene expression and several lines of evidence suggest that it acts as an 
alternate mechanism by which tumour suppressor genes are inactivated in cancer 
(Baylin et aL, 1998; Jones & Laird, 1999). However, in some cases, methylation is 
experimentally detectable but results in no gene repression. Similar to mismatch 
repair defects in cancer, methylation defects influence many different loci, and only 
some of which are pathophysiologically relevant to the neoplastic process (Toyota & 
Issa, 1999). 
Cytosine methylation is a biochemical modification of DNA and is an 
epigenetic phenomenon. In other words, it is an alteration in gene expression without 
a change in nucleotide sequence. Therefore, methylation silencing of gene expression 
1-18 
4 
Chapter 1 . Introduction 
may be reactivated by biochemical or biological manipulation (Santini et al., 2001). 
Pharmacologic inhibition of methyltransferase in vitro results in reactivation of gene 
expression for genes silenced either physiologically or pathologically (Bender et al., 
1998b). Moreover, treatment with the demethylation inhibitor 5-deoxyazacytidine 
has been shown to significantly prolong the doubling time of neoplastic cell lines but 
not normal fibroblast cell lines (Bender et al., 1998a). Furthermore, evidence has 
shown that demethylation can prevent or reverse the onset of neoplasia in animal 
models (Laird et al., 1995; Lantry et al,, 1999). Therefore, inhibition of cytosine 
methylation by demethylating agents may be one of the strategies in treating cancer. 
1.3.2 DNA methylation and EBV 
In the case of EBV, methylation of the EBV genome may ensure the survival of 
a proportion of EBV-infected cells. Silencing of the EBV promoters leads to the 
transcriptional suppression of immunodominant gene expression and thus the 
immunodominant EBNA protein expression. 
As mentioned previously, EBNA transcripts are driven from the C promoter 
(Cp), which in turn is regulated by a combination of viral and cellular proteins, 
including EBNAl, 2 and the C promoter binding factors (CBFl, 2). DNA 
methylation blocks the binding of the transcriptional activator, CBF2 (Fuentes-
Panana & Ling, 1998; Robertson et al., 1995). Also, it was demonstrated that 
methylation of the EBNA2 response element was sufficient to abolish EBNA2-
mediated Cp activity (Robertson & Ambinder，1997a). The EBNA2 responsive 
region of the Cp is methylated in EBV-infected lymphocytes in healthy seropositive 
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individuals and also in tumours with silent C promoter, such as BL, NPC, nasal 
lymphoma and Hodgkin's disease (Altiok et al., 1992; Robertson & Ambinder, 
1997b; Robertson et al., 1996). This results in a restricted EBV gene expression 
pattern. Since the products of those inactivated genes are targets of CTL, such 
suppression helps the virus to escape from host immune surveillence of the host. 
However, not all EBV promoters are susceptible to methylation. Qp appears 
never to be methylated (Tao et al., 1998b). Qp is required for EBNAl expression, 
which is crucial for viral episome maintenance, in most restricted forms of latency. It 
seems that it is excluded firom the global methylation of the viral genome in tumours 
and tumour cell lines. 
DNA methylation plays an important role in EBV biology. The suppressed 
Cp and the constitutively active Qp in EBV-associated tumours and EBV-infected 
lymphocytes shows that EBV utilizes the host cell methylation system to its 
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1.4 Demethylating Agents 
Cytidine analogues modified in position 5 of the pyrimidine ring，such as 5-
azacytidine and 5-aza-2-deoxycytidine, are potent inhibitors of DNA methylation. 5-
aza-2-deoxycytidine has a potent hypomethylating effect and can demethylate 55% 
of DNA at concentrations 10-fold lower than those of 5-azacytidine (Creusot et al., 
1982). Such demethylating action seems to be dependent on the presence of an 
altered C5 position that other cytidine analogues, such as arabinoside, 6-azacytidine, 
and gemcitabine, do not have. 
These two demethylating agents, 5-azacytidine and 5-aza-2-deoxycytidine, can 
act as an anti-neoplastic agent because of 2 distinctive mechanisms: cytotoxicity and 
induction of hypomethylation. 5-azacytidine incorporates into both RNA and DNA 
with a higher affinity to RNA while 5-aza-2-deoxycytidine mainly integrates into 
DNA. Incorporation into RNA produces disassembly of polyribosomes, defective 
methylation and acceptor function of transfer RNA, and inhibition of protein 
production (Santini et al, 2001). Integration into DNA leads to covalent linking with 
methyltransferase and blocking of DNA synthesis (Jones & Taylor, 1980)，which 
eventually results in direct cytotoxicity (Juttermaiin et al., 1994). 5-azacytidine exerts 
its action primarily on rapidly dividing cells and blocks cells from entering S phase 
while 5-aza-2-deoxycytidine does not (Covey & Zaharko, 1984; Jones & Taylor, 
1980). 
Both 5-azacytidine and 5-aza-2-deoxycytidme are anti-tumorgenic by exerting 
their demethylating effect. They covalently trap methyltransferase, which effectively 
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decreases the functional DNA methylating activity of the cells. This leads to 
hypomethylation after several rounds of DNA replication. Since DNA methylation is 
associated with suppression of gene expression，these demethylating agents are 
thought to reactivate silenced gene expression (Bender et al., 1998b). 
Moreover, both 5-azacytidine and 5-aza-2-deoxycytidine can also induce 
cellular differentiation. 5-aza-2-deoxycytidine can induce differentiation at 
concentrations that do not inhibit synthesis of protein, RNA or DNA, while the latter 
does at concentrations that inhibited DNA methylation (Attadia, 1993). 
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1.5 Aims of the Study 
EBV is a human herpesvirus that prevails globally. Over 90% adults are thought 
to be infected with EBV for life as demonstrated by the ability to recover the virus 
from their blood (Nilsson et aL, 1971). Moreover, EBV is associated with several 
malignancies including Burkitt's lymphoma (BL) and nasopharyngeal carcinoma 
(NPC). NPC, in particular, is a major health problem in Hong Kong with an 
incidence rate of 17.5/100 000/year in 1997 (Hong Kong Cancer Registry, 1997). 
In normal adults, EBV infection is controlled by the immune system, primary 
by CTLs. Different patterns of viral expression have been identified among different 
EBV-associated tumors, which are referred as different latency patterns. BL shows a 
latency I pattern with the expression of EBNAl only whereas NPC demonstrates a 
latency 11 pattern with the expression of EBNAl, LMPl, 2A and 2B. Such patterns 
of viral gene expression have been suggested to be attributed to the methylation of 
critical transcriptional regulatory elements in the C promoter (Tao et al., 1998a). This 
lack of expression of immunodominant proteins makes the tumours more difficult to 
be targeted by simple immune manipulations. It has been shown in BL cell lines that 
treatment with the demethylating agent 5-azacytidme, an DNA methyltransferase 
inhibitor，can lead to demethylation of the viral genome and expression of the 
immunodominant EBNAs in BL cell lines (Masucci et al., 1989). 
The underlying hypothesis of this thesis is that demethylating agents 
including 5-azacytidine and 5-aza-2-deoxycytidine would reactivate the silenced C 
promoter in a BL cell line, Rael and in NPC biopsies. This reactivation would induce 
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the expression of Cp-activated EBNAs including EBNA2. E B N A 2 � i n turn, 
modulates the expression of LMPl and LMP2. This would result in changes in 
latency pattern from the restricted expression pattern I or 11 to a LCL-like latency 
pattern EI. As LCL also expresses immunogenic antigens EBNAS A, 3B and 3C, it is 
believed that those demethylated cells would also express such antigens. These 
antigens are known to be potent targets of CTL with a CTL precursor frequency as 
high as 1 in 400 (Khanna et al” 1992; Murray et aL, 1992). As a result, expression of 
these antigens would reestablish immune recognition of the tumour followed by the 
CTL killing. This would allow the development of new clinical approaches that 
specifically target the virus-infected tumour cells but not normal tissue. 
Part I of this study showed the different latency patterns in the BL cell line, 
Rael, LCL and NPC tissues. Part n of this study evaluated the potency of the 
demethylating agents, 5-azacytidine and 5-aza-2-deoxycytidine, in the Rael cell line. 
The drug effects were assessed by observing alterations in EBV gene expression, cell 
growth and viability. In part EI of this study, the demethylating effect of these agents 
as investigated on NPC patient biopsy tissues with an aim to evaluate their potential 
clinical use. 
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2.1 Introduction 
During latent infection of a cell by EBV, only a subset of the viral genes is 
expressed. Based on the genes expressed three different patterns of latency have been 
defined: Latency 1,11, and III. The identification of latency patterns is hence one of the 
first steps in understanding the biology of EBV in association with its host. 
In this part of the study, 2 Burkitt's lymphoma (BL) cell lines (Rael and Raji), 1 
lymphoblastoid cell line (LCL) and 18 NPC biopsies were investigated for their 
characteristic latency pattern as a baseline for further study. 
2.2 Materials and Methods 
2.2.1 Cell line culture 
An LCL, which was established from the peripheral lymphocytes of a Caucasian 
healthy male, and an EBV-positive BL cell line, Rael, were kindly supplied by our close 
collaborator, Prof. Richard Ambinder from the Department of Oncology, Johns Hopkins 
University, USA. Another BL cell line, Raji, was kindly donated by the Department of 
Anatomical and Cellular Pathology, The Chinese University of Hong Kong. 
All cell lines were grown in RPMI 1640 medium (Gibco BRL) supplemented 
with 2mM L-glutamine (Gibco BRL), lOO^g/ml streptomycin (Gibco BRL), lOOIU/ml 
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penicillin (Gibco BRL) and 10% fetal bovine serum (Gibco BRL) (complete medium). 
The cells were incubated at 37�C in an atmosphere of 5% carbon dioxide. The cell 
density was maintained between 3x10^ and 2x10^ viable cells/ml. The generation time of 
Rael cell line was 48 hours. 
2.2.2 NPC biopsy culture 
After obtaining informed consent, fresh tumour tissue was obtained from patients 
with nasopharyngeal carcinoma undergoing endoscopic examination prior to 
radiotherapy at the Prince of Wales Hospital, Hong Kong betweeen November 1999 to 
July 2000. NPC biopsies were examined by an experienced pathologist who confirmed 
the diagnosis and the presence of tumour. After excision, the tumour tissue was 
immediately placed in cold transport medium (Appendix) on ice and transported to the 
tissue culture laboratory. 
The NPC biopsy tissue was wet-weighted before being washed three times with 
warm washing buffer (Appendix). The tissue was then finely chopped into small pieces 
approximately 1mm x 1mm and placed at a wet weight to volume ratio of 50mg/ml in 
complete medium containing SOjug/ml gentamycin (Gibco BRL), and 2.5|Lig/ml 
flmgizone (Gibco BRL). An even suspension was cultivated in 6-well tissue culture dish 
for 4 days. 
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2.2.3 RNA extraction 
RNA extraction was performed using Trizol reagent (Gibco BRL) following the 
manufacturer，s instructions. 
RNA collection from cell lines 
Cells were collected by centrifugation at 250 x g for 3 minutes at room 
temperature. The suspematent was removed and the cell pellet was resuspended in 
Trizol reagent (1x10^ cells/ml). The cells were lysed by repetitive pipetting and the 
lysate was transferred to a l.S-ml centrifuge tube and incubated for 5 minutes at room 
temperature. 
RNA collection from NPC biopsies 
Floating cells and medium were collected from the tissue culture dish and the 
cells were pelleted by centrifuging at 250 x g for 3 minutes. 1ml Trizol and 250}ig 
glycogen (Gibco BRL), a carrier for RNA precipitation, were added to the tissue culture 
wells and the cells were lysed by repetitive pipetting. The lysed cells were added to the 
cell pellet previously collected, which was then homogenized by passing through a 
pipette several times. The lysate was then transferred to a 1.5-ml centrifuge tube and 
incubated for 5 minutes at room temperature. 
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RNA precipitation 
0.2 ml of chloroform was added to each ml of Trizol reagent mixture. The tube 
was shaken vigorously by hand for 15 seconds, incubated at room temperature for 3 
minutes, and then centrifuged at 12000 x g for 15 minutes at 4°C. The colorless upper 
aqueous phase was collected. The RNA firom the aqueous phase was precipitated by 
addition of 0.5 ml of isopropyl alcohol. After overnight incubation at -20°C, the sample 
was centrifuged at 12000 x g for 10 minutes at 4°C. After discarding the supematent, the 
RNA pellet was washed with 1ml 75% ethanol in DEPC water before being centrifuged 
at 7500 X g for 5 minutes at 4°C. The supematent was removed and the RNA pellet was 
air-dried for 5 minutes before being resuspended in 10^1 DEPC-treated water. The RNA 
was stored at -80°C. 
2.2.4 RNA quantification 
The amount and quality of RNA in samples were determined using a 
spectrophotometer (GENEQUANT, Pharmacia Biotech). Samples were diluted 1:14 in 
double distilled water before measurement at 260nm in a lOjil cell. The concentration of 
RNA samples was calculated by the following formula. 
RNA concentration (|ig/inl) = Reading (OD 260nm) x 40 x dilution factor 
The ratio of the reading of260nm and 280nm (260nm:280mn) was obtained. The 
RNA quality was regarded as good if this ratio exceeded 1.7. 
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2.2.5 Deoxyribonuclease I (DNase I) treatment for NPC biopsies 
NPC RNA was treated with DNase I prior to reverse transcription to remove any 
contaminating genomic DNA following the manufacturer's instruction. Ijig of RNA sample, 
IJLIL of lOX DNase I reaction buffer and lU of DNase I and DEPC water were added to a 
final volume of 10|il into a 0.5-ml microcentrifuge tube on ice. The tube was then incubated 
for 15 minutes at room temperature before inactivating the DNase I by the addition ofEDTA 
solution to a final concentration of 2inM followed by incubation at 65°C for 10 minutes. 
2.2.6 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Oligonucleotide primers were custom-made by the Life Technology Company 
according to the sequence published by Tao (Tao et al., 1998). 
EBNAl transcripts 
The first strand cDNA was synthesized by MuLV reverse transcriptase (Applied 
Biosystems) according to the manufacturer's instructions. Briefly a mixture with final 
volume of 20}il was prepared in the proportions shown in Table 2.1. This was then 
incubated at 42°C for 15 minutes, 99°C for 5 minutes and 5°C for 5 minutes in a thermal 
cycler (MJ Research). 
A 50|j.l PGR reaction was set up as shown in Table 2.2. The mixture was then 
vortexed and briefly centrifuged before PGR. A program of 95°C for 3 minutes, 40 
cycles of 94°C for 30 seconds, the specific annealing temperature for 1 minute (Table 
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2.5) and 72°C for 1 minute followed by a 10 minutes 72°C extension step was used. 
Optimization work on annealing temperature had been performed for sharper and clearer 
banding. PGR products were then separated by gel electrophoresis (Section 2.2.7). 
0th er EB V transcripts 
First strand cDNA was synthesized by reverse transcriptase using Superscript 11 
(Gibco BRL) according to the manufacturer's instruction. 0.5jig of oligo(dT)i2-i8 was 
added to Ijug RNA in 10jj,l DEPC water followed by the incubation at 70°C for 10 
minutes. The sample was then placed on ice. After the content was collected by brief 
centrifugation, a mixture was prepared according to Table 2.3. 
This was incubated at 42°C for 2 minutes after which 200 units of Superscript n 
(Gibco BRL) reverse transcriptase was added and mixed by pipetting gently up and 
down. The mixture was incubated at 42°C for 50 minutes before stopping the reaction by 
heating at 70°C for 15 minutes. The cDNA was then stored at -20°C. 
For PGR, a mixture with a final volume of 50|LI1 was prepared as shown in Table 
2.4. This was vortexed and briefly centrifuged. The PGR conditions were as follows: 
95°C 10 minutes, 40 cycles of 94°C for 30 seconds, the specific annealing temperature 
(Table 2.5) for 1 
minute, 72°C for 1 minute and final elongation extended to 10 minutes 
at 72°C. Gel electrophoresis was then performed (Section 2.2.7). 
2-6 
播 
Chapter 2 EBV Latency Patterns 
Table 2.1 Components of Reverse Transcription Mix for EBNA1 Transcripts 
Component Volume (^ il) Final Concentration 
2 5 m M MgCl2 Solution 4 S m M 
10X P G R Gold Buffer 2 1X 
D E P C Treated M Q Water 2 -
dGTP 2 1 m M 
dATP 2 1 m M 
dTTP 2 1 m M 
dCTP 2 1 m M 
RNase Inhibitor 1 1U4il 
MuLV Reverse Transcriptase 1 2.5U/|xl 
Primer K (5'-CATTTCCAGGTCCTGTACCT) 1 0.5|iM 
R N A sample 1 1 ^ig total R N A 
Total volume 20 
Table 2.2 Components of Polymerase Chain Reaction Mix for EBNA1 Transcripts 
Component Volume (^ il) Final Concentration 
2 5 m M MgCl2 Solution 2 2 m M 
10X P G R Gold Buffer 4 1X 
D E P C Treated M Q Water 33 . 
AmpIiTaq Gold D N A Polymerase 0.25 1.25U/5〇jJ 
Primer (F/Q/Y) 0.75 0.1 
cDNA (from reverse transcription reaction) 10 
Total volume 50 
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Table 2.3 Components of Reverse Transcription Mix for EBV Transcripts 
Component Volume (^ il) Final Concentration 
5X First Strand Buffer 4 IX 
0.1MDTT 2 1 0 m M 
1 0 m M dNTP Mix 1 0.5mM  
Total volume 7 
Table 2.4 Components of Polymerase Chain Reaction Mix for EBV Transcripts 
Component Volume (^ il) Final Concentration 
25ml\/l MgCl2 Solution 4 2 m M 
10X P G R Gold Buffer 5 1X 
1 0 m M dNTP Mix 1 0.2mM 
AmpNTaq Gold D N A Polymerase 0.5 2.5U/50^I 
DEPC-treated Dl Water 35.5 -
Amplification Primer 1 1 . 5 o . 1 5 | i M 
Amplification Primer 2 1 . 5 0.15|iM 
cDNA (from reverse transcription reaction) 1 
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2.2.7 Gel electrophoresis 
1.5% (w/v) agarose gel was prepared by heating agarose (Sigma) in 0.5X tris-
borate EDTA (TBE) buffer, pH 8.3 (Sigma) to boiling in a microwave oven. Before 
pouring, the melted agarose was allowed to cool to 60°C and ethidium bromide solution 
was added to give a final concentration of 0.5|j.g/ml. 20|il PGR product was loaded into 
the wells of the solidified agarose gel in 0.5X TBE buffer and electrophoresed at 120V 
for 45 minutes in a Horizon 58 (Gibco BRL) apparatus. 
DNA was visualized with ultra-violet light at 320nm by using a UV illuminator 
(Stratagene). A polaroid photograph was taken of each gel. 
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2.3 Results 
2.3.1 Burkitt's lymphoma and lymphoblastoid cell lines 
The latency pattern of Burkitt's lymphoma cell lines, Rael and R a j i � w a s 
investigated. RT-PCR results showed that Rael expressed BART, EBNAl and LMP2A 
(Table 2.6 and Figure 2.1). In the case of EBNAl, transcripts originating from Fp (FUK) 
and Qp (QUK) were detected but no CpAVp-initiated EBNAl transcript (YUK) was 
found. 
The pattern of EBV gene expression in Raji differed from that of Rael. In 
addition to those transcripts found in Rael, Raji expressed EBNA2, LMPl, LMP2B as 
well as Cp/Wp-initiated EBNAl transcripts (Figure 2.2). 
The LCL was found to have the same expression pattern as Raji with the 
expression of BART, EBNAl, EBNA2, LMPl, LMP2A and 2B transcripts (Figure 2.3). 
These experiments were done in duplicate and are summarized in Table 2.6. 
2.3.2 Nasopharyngeal carcinoma biopsies 
RT-PCR analysis demonstrated that EBNAl transcripts originating from Qp 
were detected in all 18 biopsies (Figure 2.6). No Fp-initiated or Cp/Wp-initiated EBNAl 
transcripts was found (Figures 2.5 & 2.7). Also, no EBNA2 transcripts were found in 
any of the cases (Figure 2.8). BART transcripts were expressed in 14/18 cases (Figure 
2.4). Only 7/18 (38.9%) of biopsies expressed LMPl (Figure 2.9). The presence of 
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LMP2A and 2B were identified in 9 cases (50.0%) and 4 cases (4.5%), respectively 
(Figures 2.10 and 2.11). These results are summarized in Table 2.7. 
Table 2.6: RT-PCR Results of Burkitt's Lymphoma and Lymphoblastoid Cell Line 
EBNA1 LMP2 
Cell line BART FUK QUK YUK EBNA2 LMP1 “ 2A 2B 
BL, Rael + + + - - - + _ 
BL, Raji + + + + + + + + 
LCL + + + + + + + + 
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2.4 Discussion 
By RT-PCR, we have confirmed the presence of different EBV gene expression 
patterns in cell lines and NPC tumours investigated. A LCL demonstrated a typical 
latency III pattern with the expression of all EBNAs (1, 2, 3A, 3B, 3C, and -LP) and 
LMPs (LMPl, 2A and 2B), whereas NPC biopsies showed a latency n pattern with the 
expression of EBNAl, LMPl and LMP2. In the case of the Rael BL cell line, EBNAl 
and LMP2A transcripts were expressed, while in the Raji BL cell line, latency EI pattern 
was observed. 
Burkitt's lymphoma has been categorized as being a latency I pattern with the 
only EBNAl and BART expression (Emberg et al” 1989，Tao et al., 1998). However, 
we found that LMP2A transcripts were also detected in Rael. This is consistent with the 
results of Tao et al (Tao et al., 1998); LMP2A transcripts were detected in BL tumours. 
Because of technical difficulties in detecting LMP2 protein expression with the available 
reagents, it is unknown whether all or only a proportion of tumour cells express LMP2A. 
/n vivo studies have previously shown that LMP2A provides a survival signal to normal 
B cells (Caldwell et al, 1998). On the other hand, recent studies suggested that LMP2A 
does not promote survival of BL cells grown in culture or in models of BL 
tumourigenesis in vivo (Swart et al., 2000). The role of LMP2A in the EBV life cycle 
remains undefined. 
The Rael cell line showed the presence of BART, EBNAl and LMP2A 
transcripts with a "group 1” phenotype (Kieff, 1996). Raji, on the other hand, displayed 
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the LCL-like latency m pattern with a "group HI" phenotype (Kieff, 1996). In Rael, 
EBNAl was transcribed from the FQp promoter region while a promoter shift was 
observed in Raji (Kieff, 1996). Transcripts originating from both FQp and Cp/Wp were 
detected in Raji leading to the expression of all six EBNA species. It is believed that 
EBNA2 would activate EBNA2-mediated LMP promoters inducing the expression of 
the LMPs (Rickinson & Kieff�1996). Due to the active involvement of EBNA2 and 
LMPl in modulating cellular gene expression, it is thought that these viral transcripts are 
associated with the transition from group I to a group TH phenotype (Rickinson & Kieff, 
1996). Nevertheless, it is still largely unclear why some EBV-positive BL cell lines 
would progress from group I phenotype to a group in in vitro. Trivedi et al suggested 
that the choice of latency type may be cell- dependent and BL may opt for type I latency 
in the absence of immune pressure (Trivedi et al., 2001). 
In the case of NPC biopsies, besides BART and EBNAl, coexpression of 
expressed LMPl, LMP2A and 2B were also found in some cases. According to our 
finding, the percentage of expression of LMPl, 2A and 2B detected were 38.5, 69.2 and 
30.8’ respectively. It is surprising that, being highly immunogenic antigens, they do not 
elicit a corresponding cytotoxic immune response in vivo. This may be partly due to a 
mutation in the LMPl sequence of NPC cells (Hu et al” 1991) leading it to become 
completely nonimmunogenie for CTL when expressed in mouse carcinoma cells 
(Trivedi et al” 1994). Moreover, the CTL recognition of LMPl and LMP2 depends on 
the T-cell epitopes from these proteins processed via the TAP-independent pathway 
(Khanna et al., 1996). The recognition of LMP proteins is more efficient in TAP-
2-20 
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deficient than in TAP-positive LCLs. As a result, it is speculated that NPC may have 
evolved to retain TAP expression that limits the presentation of CTL epitopes from the 
LMP antigens, thus allowing the tumours to escape from immune-surveillance in vivo 
(Khanna & Burrows, 2000). 
The primers used in this study were adopted from Prof. Ambinder's group. 
Confirmatory analysis on current RT-PCR protocol had previously been thoroughly 
conducted by the same group. Our RT-PCR results in this chapter showed similar band 
pattern as from Prof. Ambinder's group and were in concordance with their published 
work. Since the novelty of this thesis lies in the NPC biopsies drug treatment studies, we 
took the current RT-PCR results as positive findings and proceeded with investigation 
on primary tissues. 
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Figure 2.1 RT-PCR detection of EBV transcript expression in the BL cell line, 
Rael. 
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Figure 2.4 RT-PCR detection of the P-actin transcript in NPC biopsies (1-18) and 
positive control LCL. 
Figure 2.5 RT-PCR detection of the BART transcript in NPC biopsies (1-18) and 
positive control LCL. 
Figure 2.6 RT-PCR detection of the EBNAl-FUK transcript in NPC biopsies (1-
18) and positive control LCL. 
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NPC 
LCL M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
3 � ’ ‘ 舞 … 二 
p-actin (353bp) M: 50bp Marker 
NPC 
LCL M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
BART (232bp) M: 50bp Marker 
NPC 
LCL M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
EBNA 1 - FUK (427bp) M: 50bp Marker 
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Figure 2.7 RT-PCR detection of the EBNAl-QUK transcript in NPC biopsies (1-
18) and positive control LCL. 
Figure 2.8 RT-PCR detection of the EBNAl-YUK transcript in NPC biopsies (1-
18) and positive control LCL. 
Figure 2.9 RT-PCR detection of the EBNA2 transcript in NPC biopsies (1-18) 
and positive control LCL. 
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NPC 
LCLM 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
EBNA 1 - QUK (236bp) M: 50bp Marker 
NPC 
LCL M 1 2 3 4 5 6 7 8 9 1011 12 13 14 15 16 17 18 
EBNAl - YUK (265bp) M: 50bp Marker 
NPC 
LCLm 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
EBNA2 (247bp) 
M: 50bp Marker 
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Figure 2.10 RT-PCR detection of the LMPl transcript in NPC biopsies (1-18) and 
positive control LCL. 
Figure 2.11 RT-PCR detection of the LMP2A transcript in NPC biopsies (1-18) 
and positive control LCL. 
Figure 2.12 RT-PCR detection of the LMP2B transcript in NPC biopsies (1-18) 
and positive control LCL. 
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NPC 
LCLM 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
I f P l H I ^ ^ i ^ J I 
LMPl (480bp) M: 50bp Marker 
NPC 
LCLM 1 2 3 4 5 6 7 8 9 10 11 12 131415 16 1718 
, . 觀 
LMP2A (168bp) M: 50bp Marker 
NPC 
LCLm 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
LMP2B (173bp) M: 50bp Marker 
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Chapter 3 Treatment with Demethylating Agents on Rael 
3.1 Introduction 
As demonstrated in the previous chapter, Rael, a BL cell line, displayed a type I 
EBV latency pattern that was characterized by the expression of EBNA 1 only. Such a 
restricted set of viral gene expression makes the tumour more difficult to be targeted by 
the immune system. Several lines of evidence have shown that methylation plays some 
role in regulating EBV promoters, which in turn control viral gene expression (Jansson 
et aL, 1992; Salamon et al., 2001; Tao et aL, 1998). In BL, methylation of critical 
transcriptional regulatory elements in the C promoter was found and this was thought to 
be responsible for the limited viral gene expression (Tao et al., 1998). 5-azacytidine and 
5-aza-2-deoxycytidine are DNA methyltransferase inhibitors, which can lead to 
reactivation of Cp and expression of Cp-driven antigens (Masucci et al., 1989). 
In the present study, the effects of drug treatment with the demethylating agents, 
5-azacytidine and 5-aza-2-deoxycytidine, on EBV gene expression as well as cell 
cytotoxicity and viability were investigated on Rael cells. 
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3.2 Materials and Methods 
3.2.1 Rael cell line culture 
Refer to section 2.2.1. 
3.2.2 Drug Treatment 
Drug preparation 
5-azacytidine (Sigma) and 5-aza-2-deoxycytidine (Sigma) were dissolved in 
RPMI 1640 medium (Gibco BRL) to a concentration of 2mM and stored at -80°C. This 
stock solution was fireshly diluted to a working concentration of 200|LIM prior to drug 
treatment. 
Drug treatment on Burkitt's lymphoma cell line，Rael 
20ml of Rael cells at a concentration of 3.5x10^ cells/ml were seeded into 250ml 
(75cm^) flasks (Falcon) for each time point and drug concentration to be treated. After 
allowing the cultures to grow overnight, drug was added to give a final concentration of 
0, 2, 4 or 8}xM. Cells were harvested for RNA extraction at 24, 48 and 96 hours. The 
experiment was done in duplicate. 
3.2.3 Viability staining 
0.2% (w/v) trypan blue in double distilled water was diluted 4:1 with a 4.25% 
(w/v) sodium chloride solution. 50|LI1 of a cell suspension was added to SOfil trypan blue 
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saline solution. The cells were loaded into a haemacytometer and the numbers of both 
unstained and stained cells were counted. 
3.2.4 Statistical analysis 
The viable cell number data was analyzed using Sigma Plot (version 4.0). 
Student's t-test was performed by comparing viable Rael cell numbers of control and 
drug-treated groups at different time points. 
3.2.5 RNA extraction and quantification 
Refer to section 2.2.3 and 2.2.4. 
3.2.6 RT-PCR and gel electrophoresis 
Refer to section 2.2.6 and 2.2.7 
3.2.7 DIG oligonucleotide 3，-end labeling 
Oligonucleotides were custom-made by Life Technology according to the 
sequences published by Tao (Tao et al., 1998) (Table 3.5). 
Labeling 
Oligonucleotide 3'-end labeling was performed using a DIG oligonucleotide 3'-end 
labeling kit (Roche). A mixture with a final volume of 20^1 was prepared on ice as 
shown on Table 3.1. After being mixed and centrifliged briefly, the mixture was 
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incubated at 37°C for 15 minutes and then placed on ice. The reaction was stopped by 
the addition of 2|il of 0.2M EDTA (pH 8.0). Labeled oligonucleotides were stored at 
-80�C until use. 
Efficiency test 
DIG-ddUTP labeled control oligonucleotide (2.5 pmol/jil) was diluted in dilution 
buffer in a dilution series according to Table 3.2. Experimental labeled oligonucleotide 
was prepared to a concentration of 2.5 pU/fil in dilution buffer. A 1)LI1 spot from each 
tube (Standard 1-6 and experimental labeled oligonucleotide) was applied to a strip of 
nylon H+ membrane (Pharmacia). The membrane was then cross-linked by a Cross-
linker at 1.2x10^ }jjoules (Strategene) followed by the chemiluminescent detection 
procedure described in section 3.2.8. After scanning of the X-ray film, the concentration 
of the probes were determined by comparison to the standards using the Quantity One 
software program (Biorad). The labeling efficiency of the BART, EBNAl, EBNA2, 
LMPl and LMP2 probes were 94%，83%, 53%, 56% and 59%, respectively. This is 
summarized in Tables 3.3 and 3.4. 
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Table 3.1: Components of DIG Oligonucleotide 3'-end Labeling Mix 
Reagent Volume (~.tI) Final Concentration 
1 ~M Oligonucleotide 1 100pM 
Sterile double distilled water 9 
5x Reaction buffer 4 1x 
25mM CoCI2 solution 4 5mM 
1 mM DIG-ddUTP solution 1 0.05mM 
Terminal transferase 1 2.5 units/~1 
Final volume - 20 
Table 3.2: Dilution Series of Labeled Oligonucleotide 
Tube Oligo From Tube Dilution Final 
Number (~I) Number Buffer (~I) Dilution Concentration 
Std 1 2 original 48 1:25 100fmoll~1 
(2.5pmol/~l) 
Std 2 3 Std 1 7 1:3.3 30fmoll~1 
Std 3 2 Std 1 18 1 :10 10fmoll~1 
Std 4 2 Std 2 18 1 :10 3fmol/~1 
Std 5 2 Std 3 18 1 :10 1 fmoll~1 
Std 6 20 0 
3-5 
« 
Figure 3.1 Dot blot of DIG-labeled oligonucleotide probe for the BART and 
EBNA2 transcripts. 
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Stdl Std2 Std3 Std 4 Std 5 
BART EBNA 2 
probe probe 
Table 3.3: Concentration and Labeling Efficiency of Oligonucleotide Probe for 
BART and EBNA2 Transcripts 
Name Area Mean Value Adj. Vol. Cone. Labeling 
(mm^) (ODu) (0Du*mm2) (fmol/|ii) Efficiency 
Std 1 7.44 1.01 5.02 100 -
Std 2 7.44 0.67 2.53 30 -
Std 3 7.44 0.44 0.81 10 -
Std 4 7.44 0.39 0.41 3 -
Std 5 7.44 0.35 0.15 1 -
Std 6 q ^ 0 -
BART probe 7 M ^ 93.72 94% 
EBNA2 probe 7.44 ^ 52.99 53% 
* Volume = Area x Mean Value Adjusted Volume = Volume - Background (Std 6) Volume 
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Figure 3.2 A graph showing concentration of DIG-labeled oligonucleotide probe 
for the BART and EBNA2 transcripts. 
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Figure 3.3 Dot blot of DIG-labeled oligonucleotide probe for the EBNAl, LMPl 
and LMP2 transcripts 
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Stdl Std2 Std3 Std 4 Std 5 
EBNA 1 LMP 1 LMP 2 
probe probe probe 
Table 3.4: Concentration and Labeling Efficiency of Oligonucleotide Probe for EBNA1, 
LMP1 and LMP2 Transcripts 
Name Area Mean Value Adj. Vol. Cone. Labeling 
(mm2) (ODu) (0Du*mm2) (fmol/nl) Efficiency (%) 
Std l ^ ^ 2 ^ 1 Too " 
Std 2 6.25 0.40 0.53 30 -
Std 3 6.25 0.35 0.22 10 -
Std 4 6.25 0.32 0.06 3 -
Std 5 6.25 0.32 0.07 1 -
Std 6 e ^ q ^ q ^ o -
EBNA1 probe ^ 061 ^89 83.19 83% 
LMP1 probe 6.25 0.51 1.26 55.81 56% 
LMP2 probe 6.25 1_33 58.79 59% 
* Volume = Area x Mean Volume Adjusted Volume = Volume - Background (Std 6) Volume 
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Figure 3.4 A graph showing concentration of DIG-labeled oligonucleotide probe 
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3.2.8 Southern blot 
Southern blotting 
Southern blot analysis was performed using a VacuGene XL vacuum blotting 
unit (Pharmacia). A nylon H+ membrane (Pharmacia) was wetted with 0.4M sodium 
hydroxide and positioned under the plastic mask of the blotting unit with complete 
coverage of the mask window. After gel electrophoresis, the gel was incubated in 0.4M 
sodium hydroxide for 20 minutes and gradually slid onto the membrane so as to fill the 
window. After the top frame was fitted and secured by tightening the four clamps, the 
vacuum pump was switched on to immobilize the gel. Sodium hydroxide (0.4M) was 
then poured onto the center of the gel. The gel was covered by a piece of clingwrap. The 
vacuum was stabilized at 35mbar for one hour. After blotting, the gel was removed and 
the membrane was cross-linked by a Cross-linker set to deliver 1.2x10^ {jjoules 
(Stratagene). 
Hybridization 
This was performed according to the manufacturer's instruction. 20ml DIG Easy 
Hyb (Boehringer Mannheim) was pre-warmed to the appropriate hybridization 
temperature (Table 3.5). After cross-linking, the membrane was incubated in 5X SSC 
solution for 3 minutes followed by incubation in pre-warmed hybridization buffer at the 
hybridization temperature for 2 hours. DIG-labeled oligo probe was added into 10ml 
pre-warmed hybridization buffer to a final concentration of 2 pmol/ml. The membrane 
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was incubated in the probe/DIG Easy Hyb mixture with gentle agitation overnight at the 
hybridization temperature. 
Table 3.5: Sequence and Hybridization Temperature of Different Probes 
Hybridization 
EBV Coordinate in Temperature 
Transcript Oligonucleotide Sequence B95-8 {°C)  
B f i ^ 5'-AAGACGTTGGAGGCACGCTG 157359-157378 54 
EBNA1 5'-ATGCCCTGAGACTACTCTCT 67563-67544 50 
EBNA2 5'-TGGCGTGTGACGTGGTGTAA 48397-48416 52 
LMP1 5'-AGCCCTCCTTGTCCTCTA 169325-169308 46 
LMP2 5'-ATCCAGTATGCCTGCCTGTA 62-81 50 
(Tao et al., 1998) 
Stringency washes were carried out following hybridization. The membrane was 
first washed in 2X SSC solution with 0.1% SDS for 5 minutes at room temperature 
twice followed by two more washes in O.IX SSC solution with 0.1% SDS for 15 
minutes at room temperature under constant agitation. 
DIG luminescent detection 
The DIG-labeled probe detection was performed using a DIG luminescent 
detection kit (Boehringer Mannheim) following the manufacturer's instructions. 
After hybridization and stringency washes, the membrane was rinsed in washing 
buffer (Appendix) for 3 minutes. It was then incubated in 100ml blocking solution 
(Appendix) for 1 hour. The anti-DIG-AP conjugate was diluted in blocking solution to 
75mU/ml (1:10000). The membrane was then incubated in 20ml antibody solution for 
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30 minutes before being washed with 100ml washing buffer for 15 minutes two times 
followed by equilibration in 20ml detection buffer for 5 minutes. The 
chemiluminescence substrate, CSPD, was diluted in detection buffer 1:100. The 
membrane was incubated in 10ml CSPD solution for 5 minutes. Excess liquid was 
removed by briefly touching the membrane edge to a piece of Whatman 3MM paper. 
The damp membrane was then sealed between 2 pieces of clear film before being 
incubated at 37®C for 5 minutes. The membrane was exposed to X-ray film (Kodak) at 
room temperature for 2 hours. 
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Cell growth of Rael was suppressed after treatment with 5-azacytidine (Figure 
3.5). After 24 hours of drug treatment, significant differences in viable cell number were 
detected between the control and all drug-treated groups (p<0.05) (Table 3.6). As shown 
in Figures 3.5 and 3.6, 5-azacytidine treatment caused growth suppression, and this 
effect was dosage- and time-dependent. 
The mean percentage viability of control group was 91 while that of all drug-
treated groups decreased gradually throughout the drug treatment period (Table 3.8 and 
Figure 3.7). Significant difference in percentage viability (p<0.05) between control 
group and all drug-treated groups was observed after 24-hour and also 48-hour treatment 
(Table 3.8). After treatment with 2, 4 or SjuM 5-azacytidine for 96 hours, the mean 
viability dropped to 73.9%, 66.3% and 59.2%, respectively. The duplicated results were 
consistent. 
3-13 
Chapter 4 Treatment with demethylating agents on NPC biopsies 
Table 3.6 Mean Viable Cell Number of 5-azacvtidine-treated Rael Cells 
Hours  
Drug conc. (|iM) 0 24 48 72 96 
0 5.18x1 QS 7.41X10^ 1.01X10® 2.19X10® 2.22X10® 
2 4.92x1 QS 5.30X1 CT 6.32X1 O^  8.24X10^ 8.57X10^ 
4 4.79x1 QS 4.89X1 CT 5.50X1 CT 6.93X10^ 4.85X10^ 
8 4.82x10^ 4.53x1 QS* 4.1 9X1 CT 5.02X1 O^  2.33X10^' 
* According to the result of student's t-test, significant difference was observed between drug-
treated group and control group (p< 0.05) 
Table 3.7 Cell Number (Percentage of Control) of 5-azacvtidine-treated Rael Cells 
Hours  
Drug conc. ( i^M) 0 24 48 72 96 
2 72% 6 ^ 0 37% 39% 
4 93% 67% 54% 31% 22% 
8 ^ 62% £1% 11% 
Percentage of Control = no. of drug-treated viable cells/ no. of control viable cells x 100% 
Table 3.8 Mean Viability of 5-azacvtidine-treated Rael Cells 
Hours  
Drug conc. (|iM) — Q 24 48 72 96 
0 ^ ^ 93% ^ 88% 
2 90% 88%* 82%* 80% 74% 
4 92% 86%* 81%* 76% 66% 
8 91% 86%* 77%* 70% 59%* 
* According to the result of student's t-test, significant difference was observed between drug-
treated group and control group (p< 0.05) 
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Figure 3.6 A graph showing cell number (percentage of control) of 5-azacytidine-
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Chapter 4 Treatment with demethylating agents on NPC biopsies 
EBV gene expression 
(i) RT-PCR 
RT-PCR results showed that untreated Rael cells expressed BART, EBNAl and 
LMP2A (Table 3.9 and Figures 3.8-10 & 3.14). EBNAl transcripts originating from Fp 
and Qp were detected but no CpAVp-initiated EBNAl transcripts were found (Figures 
3.9-11). Fp-initiated EBNAl transcripts were detected at low levels. 
After 5-azacytidine treatment, the presence of EBNAl transcripts originating 
from Cp/Wp were detected in all treated groups but the signals from the 24-hour-treated 
groups were weaker then those at later time points (Figure 3.11). Fp-initiated EBNAl 
became much stronger upon drug treatment (Figure 3.9). 
After 48 hours of drug treatment, the EBV expression pattern in groups treated 
with different concentrations of drug were the same as that at 24 hours except that 
EBNA2 transcripts were detected in all drug-treated groups. In the case of 96 hours of 
drug treatment, the appearance of LMPl and LMP2B transcripts were observed (Figures 
3.13 & 3.15). In all cases, BART and Qp-activated EBNAl transcripts were detected 
(Figures 3.8 & 3.10). 
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(ii) Southern blot 
Transcripts of BART and EBNA 1 from Qp were constantly detected by 
southern blot (Table 3.10 and Figures 3.8 & 3.10) in the untreated control group. 
Moreover, LMP2A transcripts were only weakly detectable (Figure 3.14). 
In all groups, including both drug-treated and untreated, BART and EBNAl 
transcripts from Qp were detected (Figures 3.8 & 3.10). After 24-hour 5-azacytidine 
treatment, EBNAl transcripts originating from Fp and CpAVp were detected (Figures 
3.9 & 3.11) and the signals from LMP2A transcripts became stronger (Figure 3.14). 
After the cells had been treated for 48 hours, the EBV expression pattern was the same 
as that found at 24-hour treatment point except for the presence of EBNA2 transcripts 
(Figure 3.12). This difference in the 48 hour treated cultures was not dependent upon the 
concentration of drug as it was found in all the drug treated cultures. LMPl transcripts 
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Figure 3.8 RT-PCR (A) and southern blot (B) detection of the BART transcript in 
5-azacytidine-treated Rael cells. 
Figure 3.9 RT-PCR (A) and southern blot (B) detection of the EBNAl-FUK 
transcript in 5-azacytidine-treated Rael cells. 
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Figure 3.10 RT-PCR (A) and southern blot (B) detection of the EBNAl-QUK 
transcript in 5-azacytidine-treated Rael cells. 
Figure 3.11 RT-PCR (A) and southern blot (B) detection of the EBNAl-YUK 
transcript in 5-azacytidine-treated Rael cells. 
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Figure 3.12 RT-PCR (A) and southern blot (B) detection of the EBNA2 transcript 
in 5-azacytidine-treated Rael cells. 
Figure 3.13 RT-PCR (A) and southern blot (B) detection of the LMPl transcript in 
5-azacytidine-treated Rael cells. 
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Figure 3.14 RT-PCR (A) and southern blot (B) detection of the LMP2A transcript 
in 5-azacytidine-treated Rael cells. 
Figure 3.15 RT-PCR (A) and southern blot (B) detection of the LMP2B transcript 
in 5-azacytidine-treated Rael cells. 
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3.3.2 5-aza-2-deoxycytidine 
Cytotoxicity 
5-aza-2-deoxycytidine treatment inhibited the growth of Rael cells (Figure 3.16). 
After 24 hours of drug treatment, significant differences in the viable cell number were 
detected between the control and all drug-treated groups (p<0.05) (Table 3.11). As 
shown in Figures 3.16 and 3.17，growth inhibition was observed and this effect was 
dosage- and time-dependent. 
The mean viability of control group was 91% (Table 3.13). However, that of all 
drug-treated groups decreased gradually throughout the drug treatment period (Figure 
3.18). It dropped to 59.5%, 52.0% and 54% in the case of 2jLiM, and 8jjM， 
respectively, after treatment with 5-aza-2-deoxycytidine for 96 hours. There was 
significant difference in percentage viability (p<0.05) between control and all drug-
treated groups at initial 24 hours. The duplicated results were in concord. 
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Table 3.11 Mean Viable Cell Number of 5-aza-2-deoxvcvtidme-treated Rael Cells 
Hours  
Drug conc. ( i^M) 0 24 48 72 96 
0 4.40x10^ 6.59x10^ 9.91x10^ 1.13x10® 1.47x10® 
2 4.31x10)5 4.36x105* 4.60x10^' 3.62x10^ 4.96x1 O^  
4 4.30x105 4.10x10®' 3.63x10^ 3.80x10^ 4.16x10^' 
8 4.31x10' 3.09x10'' 3.20x10'* 3 . 1 8 x 1 3 . 3 9 x 1 0 ' ' 
* According to the result of student's t-test, significant difference was observed between drug-
treated group and control group (p< 0.05) 
Table 3.12 Cell Number (Percentage of Control) of 5-aza-2-deoxvcvtidine-treated Rael 
Cells 
Hours  
Drug conc. (^ iM) 0 24 48 72 96 
2 98% 65% 45% 36% 34% 
4 100% 64% 39% 36% 28% 
8 ^ ^ ^ £1% 23% 
Percentage of Control = no. of drug-treated viable cells/ no. of control viable cells x 100% 
Table 3.13 Mean Viability of 5-aza-2-deoxvcvtidine-treated Rael Cells 
Hours  
Drug conc. (^ iM) Q 24 48 72 96 
0 ^ ^ 92% ^ 87% 
2 93% 82%* 77%* 65% 60% 
4 91% 81%* 74%* 65% 52%* 
8 ^ 55%* 
* According to the result of student's t-test, significant difference was observed between drug-
treated group and control group (p< 0.05) 
3-106 
Figure 3.16 Growth kinetic curve of 5-aza-2-deoxycytidine-treated Rael cells. 




















































































































Figure 3.17 A graph showing cell number (percentage of control) of 5-aza-2-
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EBV gene expression 
(i) RT-PCR 
RT-PCR results showed that the Rael control group expressed BART, EBNAl 
and LMP2A (Table 3.14 and Figures 3.19-21 & 3.25). In the case of EBNAl, Fp and 
Qp-initiated EBNAl transcripts were detected while no EBNAl transcript originating in 
Cp/Wp was found (Figure 3.22). 
After 24-hour of 5-aza-2-deoxycytidine treatment, the presence of EBNAl 
transcripts originating from Cp/Wp were detected (Figure 3.22) and the signal of Fp-
initiated EBNAl transcripts became much stronger (Figure 3.20). Moreover, weak 
signals from EBNA2 transcripts were observed (Figure 3.23) as well as enhanced signals 
of LMP2A (Figure 3.25). There were also expression of LMP2B transcripts. 
After 48-hour treatment, the EBV expression pattern was similar to that in 24-
hour treatment but with enhanced signals from EBNA2 transcripts. When the cells were 
treated for 96 hours, the presence of LMPl transcripts was also detected (Figure 3.24). 
All tested transcripts, such as BART, Fp-, Qp-, CpAVp-initiated EBNAl, EBNA2, 
LMPl, LMP2A and LMP2B, were observed in all drug-treated groups. 
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(ii) Southern blot 
Southern blot results showed the constant presence of BART transcripts and 
EBNAl transcripts from Qp in the Rael control group (Figures 3.19 & 3.21). Also, LMP 
2A transcripts were found but the signals were weak (Figure 3.25). 
Transcripts of BART and EBNAl from Qp were detected in all cases (Figures 
3.19 & 3.21). After 24-hour treatment with 5-aza-2-deoxycytidine, EBNA 1 transcripts 
were not only from Qp but also fi:om Fp and Cp/Wp (Figure 3.20-22). The signals were 
found in all drug-treated groups. Moreover, new appearance of LMP2B was observed 
and an enhanced signal firom LMP2A transcripts was noticed (Figure 3.25-26). 
When the cells were treated for 48 hours, EBNA2 transcripts was identified 
while the expression of other transcripts remained the same as those of the 24-hour drug-
treated groups. Upon 96-hour treatment, LMPl transcripts were detected (Figure 3.24). 
All tested transcripts including BART, EBNAl from Fp, Qp and Cp/Wp, EBNA2, 
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Figure 3.19 RT-PCR (A) and southern blot (B) detection of the BART transcript in 
5-aza-2-deoxycytidine-treated Rael cells. 
Figure 3.20 RT-PCR (A) and southern blot (B) detection of the EBNAl-FUK 
transcript in 5-aza-2-deoxycytidine-treated Rael cells. 
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Figure 3.21 RT-PCR (A) and southern blot (B) detection of the EBNAl-QUK 
transcript in 5-aza-2-deoxycytidine-treated Rael cells. 
Figure 3.22 RT-PCR (A) and southern blot (B) detection of the EBNAl-YUK 
transcript in 5-aza-2-deoxycytidine-treated Rael cells. 
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Figure 3.23 RT-PCR (A) and southern blot (B) detection of the EBNA2 transcript 
in 5-aza-2-deoxycytidine-treated Rael cells. 
Figure 3.24 RT-PCR (A) and southern blot (B) detection of the LMPl transcript in 
5-aza-2-deoxycytidine-treated Rael cells. 
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Figure 3.25 RT-PCR (A) and southern blot (B) detection of the LMP2A transcript 
in 5-aza-2-deoxycytidine-treated Rael cells. 
Figure 3.26 RT-PCR (A) and southern blot (B) detection of the LMP2B transcript 
in 5-aza-2-deoxycytidine-treated Rael cells. 
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3.4 Discussion 
We have demonstrated both 5-azacytidine and 5-aza-2-deoxycytidine have anti-
proliferative effects on Rael cells (Figures 3.5-6 and 3.16-17). The growth of Rael cells 
was suppressed. Significant differences in both the viable cell number and viability was 
observed between control and all drug-treated groups after 24 hours of drug treatment. 
According to the graphs of percentage of control (Figures 3.6 & 3.17), it would seem 
that 5-aza-2-deoxycytidine in the initial 24 hours was more potent than 5-azacytidine. 
However, during the rest of the drug treatment, the percentage of control of the 5-
azacytidine groups dropped gradually while that of the 5-aza-2-deoxycytidine groups 
remained stable at about 30-40%. The cytotoxicity of 5-azacytidine and 5-aza-2-
deoxycytidine may be due to their DNA binding affinity (Santini et al., 2001). It has 
been suggested that the covalent and irreversible binding of methyltransferase to drug-
substituted DNA causes direct cytotoxicity (Juttermann et al； 1994). 
Both 5-azacytidine and 5-aza-2-deoxycytidine treatment resulted in the decrease 
in the mean viability of Rael cells (Figures 3.7 & 3.18). The result is consistent with the 
finding of Masucci et al (1989). They showed that the viability of Rael cells dropped 
with incubation time upon 5-azacytidine treatment. The effect of 5-azacytidine was 
dose- and time-dependent. The mean viability decreased with time and at 96 hours, 
about 10% drop in mean viability was noticed when doubling the dosage of drug. In the 
case of 5-aza-2-deoxycytidine, its effect was different from that of 5-azacytidine. 
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Although it was also time-dependent, the mean viability of Rael cells was similar in all 
drug concentrations. 
Besides a cytotoxic effect, 5-azacytidine and 5-aza-2-deoxycytidine induce DNA 
hypomethylation. By covalently trapping methyltransferase, both agents effectively 
deplete cells of functional DNA methylating activity, which can result in profound 
hypomethylation after several rounds of DNA replication (Santini et al., 2001). In BL， 
methylation of critical transcriptional regulatory elements in the C promoter was found 
and was thought to be responsible for the limited viral gene expression (Tao et al., 
1998). Treatment with 5-azacytidine or 5-aza-2-deoxycytidine reactivates the silenced 
promoter leading to re-expression of silenced genes. Both Fp and CpAVp were re-
activated. In addition to EBNAl transcripts originating from different promoters, 
EBNA2 was also expressed. As EBNA2 can transcriptionally activate both cellular and 
viral genes, modulating the expression of certain B cell antigens, CD21 and CD23, as 
well as LMPl and LMP2 (Kieff, 1996; Wang et al., 1987; Wang et al., 1990), this 
would further activate the promoters necessary to produce the full range of latent 
proteins. 
Our results showed that EBNAl transcripts from CpAVp were detected in both 5-
azacytidine and 5-aza-2-deoxycytidine-treated groups. Even the relatively low dose of 
could induce their expression. Moreover, EBNA2 transcripts were found upon 48-
hour treatment of 5-azacytidine or 24-hour treatment of 5-aza-2-deoxycytidine at all 
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drug concentrations. As both transcripts originated from Wp/Cp, which has been shown 
to be methylated (Robertson et al.’ 1995; Tiemey et aL, 2000)，demethylation of the 
transcript YUK, i.e. Cp or Wp, can activate the expression of both EBNAl and EBNA2. 
Both drugs can induce EBV lytic cycle in cell lines (Masucci et al., 1989) and Fp is 
suggested to be a lytic promoter (Brink et al., 2001); it is not surprising that Fp-initiated 
transcripts were detected upon drug treatment. In the case of Qp, being a house-keeping 
promoter, it is always active and Qp-activated transcripts were found in all groups. 
Our results also demonstrated that the effect of the drug in altering EBV gene 
expression is not concentration-dependent at the concentration tested but time-
dependent. EBNA2 transcripts cannot be found in the 24-hour treatment group but could 
be detected upon 48- and 96-hour treatment in all 5-azacytidine-treated groups by 
Southern blot. Also, 96 hours was needed for 5-azacytidine to induce weak LMP2B 
expression and such weak signals can be observed in drug-treated groups at all 
concentrations. Longer exposure time was needed for both demethylating agents to 
initiate transcription of LMPl, as it could only be found after 96-hour treatment. It 
seems that once the treatment time is adequate, the expression of the activated 
transcripts can be detected in all drug-treated groups and difference in the drug 
concentration does not impose visible effects on alteration of EBV expression. This may 
be because of the mechanism of the drugs. These methyltransferase inhibitors work on 
daughter cells only. So time is needed for the cells to proliferate to produce enough 
demethylated DNA in cells for visualization. 
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As EBNA2 is the transactivator of LMPl, it is possible that the reactivation of 
LMPl is due to the presence EBNA2 rather than the longer exposure to the 
demethylating drugs. To differentiate the drug effect from the presence of EBNA2, one 
possible proposal is to transfect EBNA2 genes into the Rael cells, which can then be 
cultivated for 24, 48 and 96 hours. The activation pattern of LMPl transcripts as 
determined in these cultures by RT-PCR and Southern blot can then be compared to a 
parallel drug treatment experiment. 
Both 5-azacytidine and 5-aza-2-deoxycytidine were effective demethylating 
agents in terms of alteration in EBV expression. They both could reactivate silenced 
gene expression. When they are compared, it seems that 5-aza-2-deoxycytidine has a 
more potent hypomethylating effect (Creusot et al” 1982). In our Southern blot results, 
LMP2B transcripts were found in all 5 -aza-2-deoxycytidine treated groups but not in 
any of the 5-azacytidine treated counterparts. Also, RT-PCR results showed the presence 
of EBNA2 transcripts after 24-hour 5-aza-2-deoxycytidine treatment but only after 48-
hour 5-azacytidine treatment. 
After demethylating agent treatment, the EBV expression pattern shifts from 
latency I to a LCL-like latency III pattern. Besides EBNA2, LMPl and LMP2, LCL 
expresses other Cp-derived antigens including EBNA3A, 3B, 3C as well. It is believed 
that those demethylated Rael cells would also express such antigens, which are also 
immunogenic. These antigens are shown to be potent targets of CTL with a CTL 
precursor frequency as high as 1 in 400 (Khanna et al., 1992; Murray et al., 1992). 
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Therefore, expression of these antigens would re-establish immune recognition of the 
tumour followed by the killing by CTL (Robertson, 2000). 
As mentioned previously, treatment with demethylating agents can induce the 
viral lytic cycle at the same time (Masucci et al., 1989; Tao et al., 1998). This would 
reinforce the malignant cell killing in three aspects (Robertson, 2000). Firstly, when the 
viral lytic cycle occurs, tumour cells would be lysed. Secondly, the activated expression 
of lytic transcripts, such as the immunogenic immediate-early transactivator Zta, would 
in turn increase the level of CTL target antigens (Bogedain et al,, 1995). Thirdly, 
therapy could be further enhanced by additional treatment with chain-terminating 
nucleoside analogs, for example, gancyclovir, which are specifically phosphorylated by 
the lytic-cycle thymidine kinase. 
In this study, we used RT-PCR and Southern blotting to examine the presence of 
EBV transcripts. The results obtained from both analyses were generally consistent. 
However, the relatively weaker RT-PCR signals from LMP2B transcripts of 96-hour 5-
azacytidine treated group, EBNA2 transcripts in 24-hour 5-aza-2-deoxycytidine-treated 
group and Fp-initiated EBNAl transcripts in the control group were unable to be 
detected by Southern blotting. This may be due to a lower labeling efficiency of the 
probe used resulting in a general lower Southern blot sensitivity. Currently, our 
oligonucleotide probe is 3'-end labeled with a DIG-ddUTP. To enhance the sensitivity 
of our current Southern blot analysis, oligonucleotide 3 ’ tailing can be tried. Such an 
increase in the component of DIG-ddUTP in each oligonucleotide could raise the assay 
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sensitivity. Also, redesigning the probe to a bigger size and employing alternative 
labeling protocol, such as random priming, can also be tried to enhance the Southern 
blot sensitivity. 
To conclude, treatment with demethylating agents on EBV-associated BL cells 
activates silenced promoters leading to the expression of silenced genes, which are 
targets of CTL. This in turn triggers the corresponding immune response of the host. At 
the same time, such agents would also induce the viral lytic cycle, which would further 
enhance tumour cell killing. This provides a new therapeutic strategy for BL as well as 
other EBV-associated malignancies. 
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Chapter 4 Treatment with Demethylating Agents on NPC Biopsies 
4.1 Introduction 
NPC, a known EBV-associated malignancy, displays an EBV latency pattern n 
with the expression of EBNAl, LMPl, 2 A and 2B. As with BL, such a restricted pattern 
of EBV gene expression is due to the methylation of EBV promoters. It is possible that 
treating NPC biopsies with demethylating agents would result in the alteration of EBV 
gene expression pattern to that found in the BL cell line, Rael, and so as to provide a 
new therapeutic strategy for NPC. 
Up to now, there is only one EBV-positive NPC cell line, C666-1, which is a 
subclone of its parental cell line, C666, that was derived from an NPC xenograft of 
southern Chinese origin (Cheung et aL, 1999). However, when conducting this study, 
this cell line was not accessible and hence unable to include in the panel of cell lines 
under investigation. So in the present study, NPC biopsies were utilized. Demethylating 
agents, 5-azacytidine and 5-aza-2-deoxycytidine, were used to treat 14 NPC biopsies to 
investigate their effect on EBV gene expression pattern. 
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4.2 Materials and Methods 
4.2.1 NPC biopsy culture 
Refer to section 2.2.2. 
4.2.2 Drug treatment 
Drug preparation 
Refer to section 3.2.3 
Drug treatment of NPC biopsies 
The NPC biopsy was allowed to grow overnight and drug was then added. The 
drug concentrations used were 2|LIM and O.SjLiM. The concentration used were those 
adopted from Prof. Ambinder's group. RNA extraction was carried out 72 hours after 
drug addition. 
4.2.3 RNA extraction and quantification 
Refer to section 2.2.3 and 2.2.4. 
4.2.4 Deoxyribonuclease I (DNase I) treatment for NPC biopsies 
Refer to section 2.2.5. 
4.2.5 RT-PCR and gel electrophoresis 
Refer to section 2.2.6 and 2.2.7. 
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4.3 Result 
RT-PCR results showed that p-actin transcripts were present in all cases 
illustrated (Tables 4.1 & 4.2 and Figures 4.1 & 4.10). BART transcripts were only 
detected in 7/14 cases in the 5-azacytidine-treated groups (Figure 4.2) while it was 
detected in 12/14 cases in the 5-aza-2-deoxycytidine-treated groups (Figure 4.11). In the 
case of LMP2A, 3/14 cases of the 5-azacytidine-treated groups (Figure 4.8) and 8/14 
cases of the 5-aza-2-deoxycytidine-treated groups showed its presence (Figure 4.17). 
However, the presence of LMP2B transcripts was only detected in 2/14 and 3/14 cases 
in the 5-azacytidine-treated and 5-aza-2-deoxycytidme-treated groups, respectively 
(Figures 4.9 & 4.18). LMPl transcripts were found in 8/14 cases of the S-azacytidine-
treated groups (Figure 4.7) while it was found in none of the 5-aza-2-deoxycytdine-
treated groups (Figure 4.16). No EBNA2 and FUK or YUK EBNA-1 transcripts were 
found in any of the cases (Figures 4.3, 4.5, 4.6, 4.12, 4.14 & 4.15). 
4.4 Discussion 
In this study, although BART transcripts were expected to be present in 100% of 
the NPC biopsies (Brooks et al., 1993), they were not found in every sample. This may 
imply that the detection of BART transcripts is not sensitive enough as other EBV 
transcripts were found in some of those BART-negative biopsies. Based on our RT-PCR 
results of P-actin in the NPC biopsies. Intact RNA was suggested in these biopsies and 
hence the quality of RNA in RT-PCR procedures were not suspected to be sub-optimal. 
The lower frequency of BART transcripts found may thus be due to a low level of EBV 
4-3 
4 
Chapter 4 Treatment with demethylating agents on NPC biopsies 
RNA presence. Also, the limited amount of RNA quantity extracted from NPC biopsies 
has precluded Northern blot analysis for the presence of EBV RNA to be performed. 
We are aware that RT-PCR reflects the presence of PGR products with fragment 
sizes corresponding to the molecular weight of viral transcripts only. While Southern 
blot analysis should have been included in our study on NPC biopsies to confirm the 
origin of viral transcripts from RT-PCR, it was not possible to conduct such analysis due 
to the low labeling efficiency of the probe resulting in low Southern blot sensitivity (as 
discussed in Chapter 3, Section 3.4). 
In this part of study, 14 NPC biopsies were treated with demethylating agents to 
investigate the demethylating effect on EBV gene expression. While it may be 
conceived that the number of NPC biopsy analyzed in this thesis was not large enough, 
the lack of conclusive findings lied mainly on the technical difficulties in cell culture 
rather than the sample size. 
There are several problems associated with the NPC culture which include the 
inability for the biopsies suspension to attach on culture dish and grow as monolayer. 
This would affect of the demethylating treatment, of which the effectiveness was 
dependent on proliferating cells. Therefore, improvement should be made to enhance the 
survival and proliferation of the biopsies. The drug treatment may remain at 72 hours but 
the experiment should be conducted after the growth of NPC biopsies starts. This would 
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maintain the viability of the NPC cells. Also, this can prevent the NPC cells from 
contamination with other cell type, such as infiltrating lymphocytes. 
Improvements on tissue culture can mainly be categorized in two aspects 
including NPC biopsies attachment and recipe of medium. 
NPC biopsies attachment 
Epithelial tumor attachment was shown to be improved by introducing a feeder 
layer for breast cancer (Wang et al., 2001). Wang et al showed that a feeder layer of 
lethally irradiated 3T3 cells maintained tumor-derived epithelial cell proliferation and 
inhibited fibroblast attachment at the same time. This led to purification of tumor-
derived epithelial cells. As the same difficulties can also be found in primary NPC 
culture, a feeder layer of lethally irradiated 3T3 cells may also be introduced. 
Recipe of medium 
The supplement in the tissue culture medium would definitely have a close 
relationship with the growth of tissue culture in different extents. The recipe of the 
medium should be improved to facilitate the NPC cell growth. As calcium ion would 
inhibit the growth of NPC cells, serum added into the medium should be dialysed to 
eliminate or reduce the level of calcium ions. Lin et al even used serum-free medium 
with different supplements and growth factors including insulin, transferin, selenium, 
BSA，linoeic acid, hydrocortisone, cholera toxin, bovine pituitary extract, epidermal 
growth factor, endothelial cell growth supplement, 5-methyl-2-deoxycytidine and 
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nutridoma-SP (Lin et aL, 1990). Their success in establishing two NPC cell lines 
demonstrated the effectiveness of this recipe. 
If the survival and proliferation of primary NPC biopsies is improved, this would 
facilitate drug treatment with demethylating agents. As the drug is believed to act on 
proliferating cells (Santini et al., 2001), demethylation could then occur. This would 
lead to the expression of the suppressed EBV antigens, such as EBNA2. Maybe the 
demethylation in Cp will further shift NPC's EBV latency pattern from 11 to a LCL-like 
latency pattern IE similar to the case of BL. Such reactivation of EBV antigen 
expression, which is immunogenic, would be expected to trigger the corresponding 
specific cytotoxic T lymphocytes response. 
As NPC is both radiosensitive and chemosensitive, radiotherapy and 
chemotherapy is currently the mainstay of treatment for NPC. (Chan et al., 1998; van 
Hasselt & Gibb, 1999). Despite high initial control of the disease, there is still a 
significant rate of subsequent failure with distal metastasis and loco-regional relapse. 
Hence, new forms of therapy are very much needed (Chan et al., 1998). Concept of 
boosting the host's specific immune response to eliminate malignant cells provides 
another therapeutic possibility for treating NPC. Clearly, further research on in vitro and 





























































































































































































































































































Figure 4.1 RT-PCR detection of P-actin transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 0.5|iM 
5-azacytidine-treated while NPC biopsies 8-11 are 2jiM 5-azacytidine-
treated. 
Figure 4.2 RT-PCR detection of BART transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 0.5}iM 
5-azacytidine-treated while NPC biopsies 8-11 are 5-azacytidine-
treated. 
Figure 4.3 RT-PCR detection of EBNAl-FUK transcript in 5-azacytidine-treated 
NPC biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 
O.SpM 5-azacytidine-treated while NPC biopsies 8-11 are 2\jM 5-
azacytidine-treated. 
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Figure 4.4 RT-PCR detection of EBNA 1 -QUK transcript in 5-azacytidine-treated 
NPC biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 
O.SjjM 5-azacytidine-treated while NPC biopsies 8-11 are 2|iM 5-
azacytidine-treated. 
Figure 4.5 RT-PCR detection of EBNAl-YUK transcript in 5-azacytidine-treated 
NPC biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 
0.5|iM 5-azacytidine-treated while NPC biopsies 8-11 are 2|iM 5-
azacytidine-treated. 
Figure 4.6 RT-PCR detection of EBNA2 transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are O.SpM 
5-azacytidine-treated while NPC biopsies 8-11 are 2jLiM 5-azacytidine-
treated. 
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Figure 4.7 RT-PCR detection of LMP 1 transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 0.5|iM 
5-azacytidine-treated while NPC biopsies 8-11 are 2|LLM 5-azacytidine-
treated. 
Figure 4.8 RT-PCR detection of LMP2A transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control L C L . NPC biopsies 5 -7 are 0.5}JM 
5-azacytidine-treated while NPC biopsies 8-11 are 2|iM 5-azacytidine-
treated. 
Figure 4.9 RT-PCR detection of LMP2B transcript in 5-azacytidine-treated NPC 
biopsies (5-11) and positive control LCL. NPC biopsies 5-7 are 0.5|JM 
5-azacytidine-treated while NPC biopsies 8-11 are 2\xM 5-azacytidine-
treated. 
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Figure 4.10 RT-PCR detection of P-actin transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are 0.5|LIM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2}jM 5-aza-2-deoxycytidme-treated. 
Figure 4.11 RT-PCR detection of BART transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are 0.5|iM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2|iM 5-aza-2-deoxycytidine-treated. 
Figure 4.12 RT-PCR detection of EBNAl-FUK transcript in 5-aza-2-
deoxycytidine-treated NPC biopsies (12-18) and positive control LCL. 
NPC biopsies 12-14 are O.SjiiM 5-aza-2-deoxycytidine-treated while 
NPC biopsies 15-18 are 2|LIM 5-aza-2-deoxycytidine-treated. 
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Figure 4.13 RT-PCR detection of EBNAl-QUK transcript in 5-aza-2-
deoxycytidine-treated NPC biopsies (12-18) and positive control LCL. 
NPC biopsies 12-14 are O.SjiiM 5-aza-2-deoxycytidine-treated while 
NPC biopsies 15-18 are 2fiM 5-aza-2-deoxycytidine-treated. 
Figure 4.14 RT-PCR detection of EBNAl-YUK transcript in 5-aza-2-
deoxycytidine-treated NPC biopsies (12-18) and positive control LCL. 
NPC biopsies 12-14 are O.SfiM 5-aza-2-deoxycytidine-treated while 
NPC biopsies 15-18 are 2[xM 5-aza-2-deoxycytidine-treated. 
Figure 4.15 RT-PCR detection of EBNA2 transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are 0.5jiM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2|iM 5-aza-2-deoxycytidine-treated. 
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Figure 4.16 RT-PCR detection of LMPl transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are 0.5)LIM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2JLIM 5 -aza-2-deoxycytidine-treated. 
Figure 4.17 RT-PCR detection of LMP2A transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are O.SjiiM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2|LIM 5-aza-2-deoxycytidine-treated. 
Figure 4.18 RT-PCR detection of LMP2B transcript in 5-aza-2-deoxycytidine-
treated NPC biopsies (12-18) and positive control LCL. NPC biopsies 
12-14 are 0.5juM 5-aza-2-deoxycytidine-treated while NPC biopsies 
15-18 are 2faM 5-aza-2-deoxycytidine-treated. 
I 
Chapter 4 Treatment with demethylating agents on NPC biopsies 
NPC 
LCL 12 12AD 13 13AD 14 14AD 15 15AD 16 16AD 17 17AD 18 18AD 
|，/,> - § ‘ •象貧-麵磁魏顯没fey"�:::: '么::::,:、-
LMPl 
NPC 
LCL 12 12AD 13 13AD 14 14AD 15 15AD 16 16AD 17 17AD 18 18AD 
LMP2A 
NPC 




Chapter 5 Conclusion 
Chapter 5 Conclusion 
To conclude, this study showed different latency patterns in different EBV 
positive cell lines and NPC biopsies. Also, it demonstrated the effects of demethylating 
agents, 5-azacytidine and 5-aza-2-deoxycytidine, on BL cell line, Rael. Both agents 
resulted in suppressed Rael cell growth with reduced mean viability. The cytotoxic 
effect of 5-azacytidine was time- and dose-dependent while 5-aza-2-deoxycytidine was 
time-dependent only. Both agents could reactivate silenced viral gene expression but it 
seems that 5-aza-2-deoxycytidine has a more potent hypomethylating effect (Creusot et 
al； 1982). In our southern blot results, LMP2B transcripts were found in all 5-aza-2-
deoxycytidine treated groups but not in any of the 5-azacytidine treated counterparts. 
Moreover, it showed the possibility to shift the restricted EBV latent gene expression 
pattern to the LCL-like pattern by introducing these demethylating agents to Rael cells. 
Reactivation of the silenced Cp resulted in the expression of immunogenic antigens such 
as EBNA2, LMPl and 2. Such effect was time-dependent. It is believed that other Cp-
driven immunogenic antigens including EBNA3A, 3B and 3C would also be expressed. 
This would reestablish the specific immune response of the host to the tumour 
facilitating the killing of the tumour cells by CTL. This provides another strategy for 
cancer therapy. 
The results obtained from cell line model with the two demethylating agents 
were further extended to NPC biopsies. Unfortunately, the inconsistence of in vitro 
5-1 
Chapter 5 Conclusion 
proliferation, as found in my study, has hindered the interpretation of the effectiveness 
of the drug treatment. The effects of the demethylating agents could not be demonstrated 
and no observable differences between two agents could be found. This is likely due to 
the immature tissue culture protocol employed in this thesis. As the in vitro cellular 
proliferation of NPC is essential for the proposed demethylation work, it is therefore 
proposed for future studies to improve on culture medium, enhance attachment of 
desegregated NPC tissues by introducing a feeder layer, and to evaluate different types 
of collagenase enzymes in tissue digestion. It is believed that the demethylating effect of 
the drugs can be investigated in depth only if effective improvements on NPC biopsy 
culture techniques can be made 
Further studies are needed to investigate the effect of demethylating agents on 
EBV-positive cells. Bisulfite treatment of genomic DNA and methylation-specific PCR 
can be employed to demonstrate the dosage and time effect of the demethylating agents 
on the methylation status of EBV promoters. As RT-PCR and southern blot mainly 
detect the expression changes in transcriptional level, investigation of the corresponding 
changes in translational level is suggested for future studies. Immunostaining and 
western blot can be performed to detect the protein expression. However, due to the 
limitation of antibody availability, only expression of EBNA2 and LMPl antigens can 
be further demonstrated. 
This study suggests the effectiveness of altering EBV gene expression after 
treatment with demethylating agents in Rael cell line. However, effort is still needed to 
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establish such a model on biopsies or epithelial cells. Success on this would further 
enhance the role of immunotherapy in treating cancers, such as NPC, and provide us 
another therapeutic possibility. 
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Appendix 
Buffers and Reagents 
Tissue Culture 
Complete medium for cell line culture 
1 • RPMI 1640 Gibco BRL, Life Technologies, USA 
2. 10% Fetal Bovine Serum Gibco BRL, Life Technologies, USA 
3. 2mM L-glutamine Gibco BRL, Life Technologies, USA 
4. Penicillin/ streptomycin Gibco BRL, Life Technologies USA 
(100IU/ml and 100mg/ml) 
NPC transport medium (4°C) 
1. RPMI 1640 Gibco BRL, Life Technologies, USA 
2. 10% Fetal Bovine Serum Gibco BRL, Life Technologies, USA 
3. Gentamycin (100|ig/ml) Gibco BRL, Life Technologies, USA 
4. Fungizone (2.5|ig/mi) Gibco BRL, Life Technologies, USA 
5. Penicillin/ streptomycin Gibco BRL, Life Technologies USA 
{100IU/ml and 100mg/ml) 
Washing buffer for NPC biopsies 
1. Hank's balanced salt solution Gibco BRL, Life Technologies, USA 
2. Gentamycin (100|ig/ml) Gibco BRL, Life Technologies,' USA 
3. Fungizone (2.5^ig/ml) Gibco BRL, Life Technologies, USA 
4. Penicillin/ streptomycin Gibco BRL, Life Technologies, USA 
(100IU/ml and 100mg/ml) 
Culture medium for NPC biopsies 
1. RPMI 1640 Gibco BRL, Life Technologies, USA 
2. 10% Fetal Bovine Serum Gibco BRL, Life Technologies, USA 
3. 2mM L-glutamine Gibco BRL, Life Technologies, USA 
4. Gentamycin (50|ig/ml) Gibco BRL, Life Technologies, USA 
5. Fungizone (2.5|ig/ml) Gibco BRL, Life Technologies, USA 
6. Penicillin/ streptomycin Gibco BRL, Life Technologies, USA 
(100IU/ml and 100mg/ml) 
5-azacytidine Sigma, St Louis, MO, USA 
5-aza-2-deoxycytidine Sigma, St Louis, MO, USA 
RNA Extraction 
Trizo丨 reagent Gibco BRL, Life Technologies, USA 
Glycogen Gibco BRL, Life Technologies, USA 
Chloroform Sigma, St Louis, MO, USA 




1 • 75ml 100% ethanol Merck, Darmstadt, Germany 
2. 25ml DEPC-treated water 
DEPC-treated water 
1. 500ml MQ water _ 
2. 500|il DEPC Sigma, St Louis, MO, USA 
Dnase 丨 Treatment 
Deoxyribonuclease I (amplification grade) Gibco BRL, Life Technologies, USA 
10X DNase I reaction buffer Gibco BRL, Life Technologies USA 
1.200mM Tris-HCI (pH 8.4) 
2. 20mM MgCl2 
3. 500mM KCi 
25mM EDTA (pH 8.0) Gibco BRL, Life Technologies. USA 
RT-PCR 
MuLV reverse transcriptase Roche, Applied Biosystem, USA 
Superscript II Gibco BRL, Life Technologies, USA 
AmpliTaq gold DNA polymerase Roche, Applied Biosystem, USA 
RNase inhibitor Roche, Applied Biosystem, USA 
10X PGR gold buffer Roche, Applied Biosystem, USA 
1. 150mM Tris-HCI, pH 8.0 
2. 500mM KCI 
5X first strand buffer Gibco BRL. Life Technologies, USA 
1. 250mM Tris-HCI (pH 8.3) 
2. 375mM KCI 
3. 15mM MgCl2 
0.1 DTT Gibco BRL, Life Technologies, USA 
25mM Magnesium chloride Roche, Applied Biosystem, USA 
dATP Roche, Applied Biosystem, USA 
dCTP Roche, Applied Biosystem, USA 
dGTP Roche, Applied Biosystem, USA 
dTTP Roche, Applied Biosystem, USA 
A-2 
1 
Oligo(dT)i2-i8 Gibco BRL, Life Technologies, USA 
Gel Electrophoresis 
Agarose Sigma, St Louis, MO, USA 
5X TBE Sigma, St Louis, MO, USA 
6X Gel loading solution Sigma, St Louis, MO, USA 
DIG Oligonucieotide 3'-End Labeling 
5X Reaction buffer Boehringer Mannheim, Germany 
1. 1M potassium cacodylate 
2. 125mMTris-HCI 
3. 1.25mg/ml bovine serum albumine, pH 6.6 
25mM C0CI2 Boehringer Mannheim, Germany 
1mM DIG-ddUTP Boehringer Mannheim, Germany 
Terminal transferase Boehringer Mannheim, Germany 
DNA dilution buffer Boehringer Mannheim, Germany 
1. 50|_ig/ml herring sperm DNA 
2. 10mM Tris-HCI 
3. 1mM EDTA, pH 8.0 
Southern Blot 
Sodium hydroxide Sigma, St Louis, MO, USA 
Hybridization 
DIG Easy Hyb Boehringer Mannheim, Germany 
Detection 
20X SSC 
1. 3M NaCI Riedel-de-Haen, Germany 
2. 0.3M Sodium citrate Riedel-de-Haen, Germany 
3. Double distilled water -
SDS Riedel-de-Haen, Germany 
10X Washing buffer Boehringer Mannheim, Germany 
1. 10X Maleic acid buffer 
2. 3% Tween 20 
A-3 
« 
10X Maleic acid buffer Boehringer Mannheim, Germany 
10X Blocking solution Boehringer Mannheim, Germany 
1. 10% Blocking reagent 
2. 450ml Maleic acid buffer 
10X Detection buffer Boehringer Mannheim, Germany 
1. 1MTris-HCI, pH 9.5 
2. 1M NaCI 
Anti-digoxigenin-AP, Fab fragments Boehringer Mannheim, Germany 
CSPD Boehringer Mannheim, Germany 
A-4 
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